Multi-step filtration and clarification method for recombinant adeno-associated virus purification

By employing a multi-stage filtration system that combines a pre-filter, a depth filter, an anion exchanger, and a bioload reduction filter, the problem of impurity removal in rAAV preparations has been solved, achieving efficient impurity removal and product retention, making it suitable for high cell density production.

CN123125037APending Publication Date: 2026-11-17ULTRAGENYX PHARMACEUTICAL INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202580029558.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-05-09
Filing Date
2025-04-21
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies are ineffective at removing impurities from recombinant adeno-associated virus (rAAV) preparations, especially in high-cell-density production. Conventional filtration methods are unable to effectively remove particulate impurities, host cell debris, and helper virus particles, leading to filter clog and product loss.

Method used

A multi-stage filtration system is used to remove impurities, including cell complexes, colloidal aggregates, and adenovirus particles, from rAAV production cell lysates by employing a combination of pre-filters, depth filters, anion exchange adsorbent media, and bioload reduction filters.

Benefits of technology

It improves the purity of rAAV preparations, reduces filter clogging, enhances filter capacity and throughput, and ensures efficient impurity removal and product retention, making it suitable for high cell density production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123125037A_ABST
    Figure CN123125037A_ABST
Patent Text Reader

Abstract

Systems and methods are provided for separating adeno-associated virus (rAAV) particles from host cell-derived impurities and other byproducts from preparations produced from host cell cultures.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references to related applications

[0002] This application claims the benefit and priority of U.S. Provisional Patent Application No. 63 / 637,054, filed April 22, 2024, and U.S. Provisional Patent Application No. 63 / 644,663, filed May 9, 2024, the disclosures of which are incorporated herein by reference in their entirety for all purposes. Background Technology

[0003] Recombinant adeno-associated viruses (rAAVs) engineered to carry target heterologous nucleic acids (e.g., genes encoding therapeutic proteins, antisense nucleic acid molecules, ribozymes, miRNAs, siRNAs, nucleic acids encoding the CRISPR / Cas system, etc.) are increasingly being explored as therapeutic agents for various diseases. These rAAVs are engineered by deleting all or part of the internal portion of the AAV genome and inserting the target heterologous nucleic acid between inverted terminal repeat sequences (ITRs). The ITRs retain functionality in such rAAVs, allowing for the replication and packaging of rAAV particles containing nucleic acid cargo encapsulated within the AAV capsid. Typically, the heterologous nucleic acid is operatively linked to regulatory sequences (e.g., promoter and / or enhancer sequences) capable of driving the expression of the cargo in the patient's target cells.

[0004] To reduce the cost of products and increase patient access to rAAV-based therapies, there is a growing demand for large-scale manufacturing of rAAV cell cultures using increased cell density. However, the large-scale manufacturing of these rAAVs can be hampered by the presence of impurities in the rAAV preparation, which may include particulate impurities, host cell debris, host cell proteins, and helper viral particles. Conventional filtration protocols utilize depth filters designed for purifying conventional biologics, such as monoclonal antibodies and recombinant proteins. Filters and filtration protocols known in the art are not optimized for the impurity profile of the crude harvest derived from rAAV production cell lines. At the high volumetric productivity of rAAV production, the increased impurity load hinders the practical use of conventional filtration protocols.

[0005] This application addresses the challenge of effectively removing impurities from rAAV preparations obtained from production cell lines by implementing a filtration scheme tailored to remove specific impurities that primarily cause fouling in clarifier filters. This disclosure provides methods for adding pre-filters to reduce cells, cell aggregates, and cell debris to enhance the capacity of primary depth filters, and for replacing conventional depth filters with anion exchanger media to remove negatively charged colloids and increase the throughput through bioload-reducing filters. Summary of the Invention

[0006] Clarifying rAAV production cell lysates to remove contaminants (including, but not limited to, host cell-derived impurities and helper viral particles) is a crucial step before purifying rAAV products. Most clarification methods known in the art rely on a combination of one or more depth filters and bioload-reducing filters. There is a need in the art for novel clarification methods and systems to efficiently remove impurities from rAAV production cell lysates to produce high-purity preparations for further downstream purification of rAAV-based pharmaceutical products. This disclosure provides methods and systems for clarifying rAAV production cell lysates using a combination of pre-filters, depth filters, anion exchange chromatography (AEX) filters, and bioload-reducing filters. Such combinations differ from known rAAV clarification methods and systems and overcome previous operational problems, including potential loss of product rAAV material and buildup clogging of filter media.

[0007] This disclosure provides methods for clarifying cell lysates produced from cell cultures expressing recombinant adeno-associated virus (rAAV) particles, the methods comprising: (a) passing the cell lysates through a pre-filter medium to generate a first filtrate; (b) passing the first filtrate through a depth filter medium to generate a second filtrate; (c) passing the second filtrate through an anion exchanger medium to generate a third filtrate; and (d) passing the third filtrate through a bioload reduction filter to generate clarified cell lysates.

[0008] In some embodiments of the method disclosed herein, the cell lysate is produced from cells with a density of approximately 1 × 10⁻⁶ cells. 6 To approximately 2 × 10 7 The cell lysate is generated from a cell culture expressing rAAV at a density of at least about 10 cells / mL. In some embodiments of the method disclosed herein, the cell lysate is generated from a cell density of at least about 10 cells / mL. 6 The cell lysate is generated from a cell culture expressing rAAV at a density of at least about 8 × 10⁶ cells / mL. In some embodiments of the method disclosed herein, the cell lysate is generated from a cell density of at least about 8 × 10⁶ cells / mL. 6 To approximately 2 × 10 7 The cell culture expressing rAAV was produced at a rate of 1 cell / mL.

[0009] In some embodiments of the methods disclosed herein, the cell lysates have a pH of about 7.5 to about 8.0. In some embodiments of the methods disclosed herein, the cell lysates have a pH of about 7.7 to about 7.9.

[0010] In some embodiments of the methods disclosed herein, the cell lysate comprises rAAV particles and one or more of the following: cell complexes, cell aggregates, colloidal aggregates, nucleases, nucleic acids, host cell proteins, lysed cell fragments, and nucleotide fragments.

[0011] In some embodiments of the method disclosed herein, the clarified cell lysate contains rAAV particles. In some embodiments of the method disclosed herein, the clarified cell lysate retains at least 80% of the total rAAV particles present in the cell lysate. In some embodiments of the method disclosed herein, the clarified cell lysate retains ≥ 85% of the total rAAV particles present in the cell lysate.

[0012] In some embodiments of the methods disclosed herein, the cell lysate contains helper viral particles. In some embodiments of the methods disclosed herein, the helper viral particles are adenovirus particles. In some embodiments of the methods disclosed herein, the adenovirus particles are adenovirus serotype 5 (Ad5) particles.

[0013] In some embodiments of the method disclosed herein, the cell lysate contains a density of approximately 1 × 10⁻⁶. 12 To approximately 3 × 10 12 GC / ml Ad5 particles. In some embodiments of the method disclosed herein, the total amount of Ad5 particles in the filtrate volume loaded onto the anion exchange filter is approximately 3 × 10⁻⁶. 16 To approximately 5 × 10 16 GC / L membrane volume (GC / L-MV). In some embodiments of the method disclosed herein, the total amount of Ad5 particles in the filtrate volume loaded onto the anion exchange filter is approximately 3 × 10⁻⁶. 16 From approximately 7.25 × 10 16 GC / L-MV.

[0014] In some embodiments of the method disclosed herein, the volume of the cell lysate is at least 50 L. In some embodiments of the method disclosed herein, the volume of the cell lysate is at least 250 L. In some embodiments of the method disclosed herein, the volume of the cell lysate is between about 50 L and about 250 L.

[0015] In some embodiments of the method disclosed herein, the pre-filter medium has a pore size of about 20 μm to about 75 μm. In some embodiments of the method disclosed herein, the pre-filter medium has a pore size of about 50 μm.

[0016] In some embodiments of the method disclosed herein, passing cell lysates through a pre-filter medium increases the volumetric capacity of the depth filter by at least 25%. In some embodiments of the method disclosed herein, passing cell lysates through a pre-filter medium increases the filtration capacity of the depth filter by about 30 to about 50 L / m³. 2 .

[0017] In some embodiments of the method disclosed herein, the flow rate of cell lysate in the pre-filter medium is from about 225 to about 925 L / m. 2 h. In some embodiments of the method disclosed herein, the pre-filter medium has a concentration of about 300 to about 700 L / m³. 2 The volumetric capacity. In some embodiments of the method disclosed herein, the pressure differential in the pre-filter medium is about 1 to about 5 psi.

[0018] In some embodiments of the methods disclosed herein, the depth filter medium comprises any one of cellulose-based filter media, glass-based filter media, and acrylic acid-based filter media. In some embodiments of the methods disclosed herein, the depth filter medium comprises 2 to 8 layers of filter media. In some embodiments of the methods disclosed herein, the depth filter further comprises any one of diatomaceous earth (DE) filter aid and silica filter aid. In some embodiments of the methods disclosed herein, the depth filter medium comprises at least one polypropylene fiber pulp, a nonwoven fiber layer, or a combination thereof. In some embodiments of the methods disclosed herein, the depth filter medium further comprises a cationic binder.

[0019] In some embodiments of the method disclosed herein, the flow rate of the first filtrate in the depth filter medium is about 50 to about 150 L / m. 2 h. In some embodiments of the method disclosed herein, the volumetric capacity of the depth filter media is about 70 to about 200 L / m³. 2 In some embodiments of the method disclosed herein, the pressure differential in the depth filter medium is about 1 to about 18 psi.

[0020] In some embodiments of the disclosed method, the depth filter medium comprises a first layer of cellulose fibers and a second layer of cellulose, diatomaceous earth (DE) filter aid, and cationic binder. In some embodiments of the disclosed method, the depth filter medium comprises a first layer of nonwoven fibers, a second layer of polypropylene fiber pulp, and third and fourth layers comprising polyacrylic acid fiber pulp, silica filter aid, and cationic binder. In some embodiments of the disclosed method, the depth filter medium comprises six layers of polypropylene fibers and nonwoven fibers, a second layer of cellulose fibers, and a third layer of cellulose, diatomaceous earth (DE) filter aid, and cationic binder. In some embodiments of the disclosed method, the anion exchange adsorber medium is either a strong anion exchange chromatography (AEX) medium or a mixture of AEX media.

[0021] In some embodiments of the method disclosed herein, the strong AEX medium is Sartobind. ® Q medium, Mustang ®Q medium or Natrix ® Any of the following media: AEX mixed media. In some embodiments of the method disclosed herein, the AEX mixed media comprises an AEX chromatographic medium and a polyamide membrane. In some embodiments of the method disclosed herein, the AEX mixed media comprises an AEX chromatographic medium and a polyethersulfone (PES) membrane. In some embodiments of the method disclosed herein, the AEX chromatographic medium is a quaternary ammonium salt functionalized AEX medium. In some embodiments of the method disclosed herein, the quaternary ammonium salt functionalized AEX medium is a nonwoven medium. In some embodiments of the method disclosed herein, the AEX chromatographic medium is Harvest... ® RC media or Emphaze ® Any type of AEX medium.

[0022] In some embodiments of the method disclosed herein, the pore size of the polyamide membrane or PES membrane is from about 0.1 to about 0.5 μm. In some embodiments of the method disclosed herein, the pore size of the polyamide membrane or PES membrane is 0.2 μm. In some embodiments of the method disclosed herein, the flow rate of the first filtrate in the anion exchange adsorber medium is from about 50 to about 200 L / m³. 2 h. In some embodiments of the method disclosed herein, the volumetric capacity of the anion exchange adsorber medium is about 70 to about 200 L / m³. 2 In some embodiments of the methods disclosed herein, the pressure differential of the anion exchange adsorber medium is about 1 to about 10 psi. In some embodiments of the methods disclosed herein, the filter load conductivity of the adsorber medium is about 16 to about 40 mS / cm. In some embodiments of the methods disclosed herein, the filter load conductivity is about 18 to about 37 mS / cm.

[0023] In some embodiments of the method disclosed herein, the bioburden reduction filter comprises any one of a polyvinylidene fluoride (PVDF)-based filter, a PES-based filter, and a polyamide-based filter. In some embodiments of the method disclosed herein, the flow rate of the third filtrate through the bioburden reduction filter is approximately 300 to approximately 700 L / m³. 2 h. In some embodiments of the method disclosed herein, the volumetric capacity of the bioburden reduction filter is about 500 to about 750 L / m³. 2 In some embodiments of the method disclosed herein, the differential pressure limit of the bioburden reduction filter is about 20 to about 25 psi.

[0024] This disclosure also provides a system for clarifying cell lysates produced from cell cultures expressing recombinant adeno-associated virus (rAAV) particles, the system comprising: (a) a first module including a pre-filter medium that filters the cell lysates to remove particulate matter ≥ 50 μm in size from the cell lysates to generate a first filtrate; (b) a second module including a depth filter medium that filters the first filtrate to remove particulate matter ≥ 1 μm to < 50 μm in size from the first filtrate to generate a second filtrate; (c) a third module including an anion exchanger medium that filters the second filtrate to remove adenovirus particles from the second filtrate to generate a third filtrate; and (d) a fourth module including a bioload reduction filter that filters the third filtrate to remove microbial contaminants from the third filtrate to generate clarified cell lysates.

[0025] In some embodiments of the system disclosed herein, the cell lysate is produced from cells with a density of approximately 1 × 10⁻⁶ cells. 6 To approximately 2 × 10 7 The cell lysate is generated from a cell culture expressing rAAV at a density of approximately 10 cells / mL. In some embodiments of the system disclosed herein, the cell lysate is generated from a cell density of approximately 10 cells / mL. 6 The cell lysate is generated from a cell culture expressing rAAV at a density of approximately 6 × 10⁶ cells / mL. In some embodiments of the system disclosed herein, the cell lysate is generated from a cell density of approximately 6 × 10⁶ cells / mL. 6 To approximately 2 × 10 7 The cell culture expressing rAAV was produced at a rate of 1 cell / mL.

[0026] In some embodiments of the system disclosed herein, the cell lysate has a pH of about 7.5 to about 8.0. In some embodiments of the system disclosed herein, the cell lysate has a pH of about 7.7 to about 7.9.

[0027] In some embodiments of the system disclosed herein, the helper virus adenovirus particles are adenovirus particles. In some embodiments of the system disclosed herein, the adenovirus particles are Ad5 particles. In some embodiments of the system disclosed herein, the cell lysate contains a density of approximately 1 × 10⁻⁶. 12 To approximately 3 × 10 12 GC / ml Ad5 particles. In some embodiments of the method disclosed herein, the total amount of Ad5 particles in the filtrate volume loaded onto the anion exchange filter is approximately 3 × 10⁻⁶. 16 To approximately 5 × 10 16GC / L-MV. In some embodiments of the method disclosed herein, the total amount of Ad5 particles in the filtrate volume loaded onto the anion exchange filter is approximately 3 × 10⁻⁶. 16 From approximately 7.25 × 10 16 GC / L-MV.

[0028] In some embodiments of the system disclosed herein, the volume of cell lysate is at least 50 L. In some embodiments of the system disclosed herein, the volume of cell lysate is at least 250 L.

[0029] In some embodiments of the system disclosed herein, the pre-filter medium is any one of a polypropylene fleece-based pre-filter, a pre-filter based on absorbent glass fleece material, a mixed cellulose ester, a nylon membrane pre-filter, a glass and quartz fiber pre-filter, polyvinyl chloride, and polytetrafluoroethylene. In some embodiments of the system disclosed herein, the pre-filter medium has a pore size of about 20 micrometers (μm) to about 75 μm. In some embodiments of the system disclosed herein, the pre-filter medium has a pore size of about 50 μm.

[0030] In some embodiments of the system disclosed herein, the depth filter medium is any one of cellulose-based, glass-based, and acrylic-based filter media. In some embodiments of the system disclosed herein, the depth filter medium comprises 2-8 layers of filter media. In some embodiments of the system disclosed herein, the depth filter further comprises any one of diatomaceous earth (DE) filter aid and silica filter aid. In some embodiments of the system disclosed herein, the depth filter medium comprises at least one polypropylene fiber pulp, a nonwoven fiber layer, or a combination thereof. In some embodiments of the system disclosed herein, the depth filter medium further comprises a cationic binder.

[0031] In some embodiments of the system disclosed herein, the depth filter medium comprises a first layer of cellulose fibers and a second layer of cellulose, diatomaceous earth (DE) filter aid, and cationic binder. In some embodiments of the system disclosed herein, the depth filter medium comprises a first layer of cellulose fibers and a second layer of cellulose, diatomaceous earth (DE) filter aid, and cationic binder; the depth filter medium comprises a first layer of nonwoven fibers, a second layer of polypropylene fiber pulp, and third and fourth layers of polyacrylic acid fiber pulp, silica filter aid, and cationic binder. In some embodiments of the system disclosed herein, the depth filter medium comprises six layers of polypropylene fibers and nonwoven fibers, a second layer of cellulose fibers, and a third layer of cellulose, diatomaceous earth (DE) filter aid, and cationic binder.

[0032] In some embodiments of the system disclosed herein, the anion exchange adsorber medium is either a strong AEX medium or a mixed AEX medium. In some embodiments of the system disclosed herein, the strong AEX medium is Sartobind. ® Q medium, Mustang ® Q medium or Natrix ® Any of the following media: AEX mixed media. In some embodiments of the system disclosed herein, the AEX mixed media includes an AEX chromatographic medium and a polyamide membrane. In some embodiments of the system disclosed herein, the AEX mixed media includes an AEX chromatographic medium and a polyethersulfone (PES) membrane. In some embodiments of the system disclosed herein, the AEX chromatographic medium is a quaternary ammonium salt functionalized AEX medium. In some embodiments of the system disclosed herein, the quaternary ammonium salt functionalized AEX medium is a nonwoven medium. In some embodiments of the system disclosed herein, the AEX chromatographic medium is Harvest... ® RC media or Emphaze ® Any of the AEX media. In some embodiments of the system disclosed herein, the pore size of the polyamide membrane or PES membrane is between about 0.1 and about 0.5 μm. In some embodiments of the system disclosed herein, the pore size of the polyamide membrane or PES membrane is 0.2 μm. In some embodiments of the system disclosed herein, the bioburden reduction filter can be any of a PVDF-based filter, a PES-based filter, and a polyamide-based filter. Attached Figure Description

[0033] Figure 1A-1B The conventional filter train disclosed herein is described. Figure 1A ) and multi-level filtering sequences ( Figure 1B A schematic diagram is provided to illustrate high-cell-density rAAV production.

[0034] Figure 2A-2B Depicting a pre-filter ( Figure 2A ) and without pre-filter ( Figure 2B A comparison of the depth filter pressure profiles. The x-axis depicts the throughput (L / m). 2 The y-axis depicts the pressure differential (psid). The pressure differential profile relative to throughput velocity in the presence of depth and pre-filters is shown in the curves.

[0035] Figures 3A-3C A comparison of the effects of conventional depth filters and adsorption filters on the throughput capacity of bioburden reduction filters is depicted. The following filters are connected in series as indicated: i) Conventional depth filter and bioburden reduction filter ( Figure 3A ); ii) Adsorption filter A and bioburden reduction filter ( Figure 3B ); and iii) Adsorption filter B and bioburden reduction filter ( Figure 3C ).

[0036] Figure 4 A comparison of pressure profiles for various adsorbent media is depicted. The x-axis indicates the throughput of the rAAV preparation through the indicated filter media, and the y-axis indicates the pressure differential.

[0037] Figure 5 The harvest clarification filter pressure profile of a multi-stage filter string produced at a scale of 50-L is depicted. The y-axis indicates the inlet pressure of each filter in the multi-stage filter string, corresponding to the throughput rate indicated by the x-axis.

[0038] Figure 6 A comparison of turbidity measurements between the crude harvest and the clarified filtrate produced from two pilot-scale batches (Production Batch 1 and Production Batch 2, as indicated) using the clarification and filtration system disclosed herein is depicted. The y-axis indicates the turbidity measurements (Nephelometric Turbidity Units, NTUs), as indicated, for samples of feed material (blank column) and clarified filtrate (black column) from Production Batch 1 and 2.

[0039] Figure 7 The elution profile and conductivity variation (dashed line) of rAAV particles corresponding to the elution volume (x-axis) are depicted. The level of eluted rAAV particles is indicated by the absorption at UV280 and UV254, represented by thick black lines and thin black lines, respectively, as indicated by the left y-axis. Figure 7 The variation of relative conductivity (corresponding to the right y-axis) with increasing elution volume was also depicted.

[0040] Figure 8 The dynamic binding capacity of the anion exchange filter and the Ad5 breakthrough concentration in the loading material are depicted. The Ad5 retention level corresponding to the amount of Ad5 in the loading material (GC / L-MV) is indicated on the x-axis. The sampling frequency (number of samples obtained per second) is indicated on the y-axis. The percentage of Ad5 retained from the loading material on the anion exchange filter, as indicated, corresponds to the amount of Ad5 within the filter's dynamic binding capacity (DBC), the amount leading to acceptable Ad5 breakthrough, and the amount leading to undesirable breakthrough range, as indicated. Detailed Implementation

[0041] definition

[0042] Unless otherwise expressly stated, where the term “about” is used before a quantitative value, this disclosure covers the specific quantitative value itself (e.g., “about 10% to about 20%” should be understood to include “10% to 20%”, as well as “about 10% to 20%” and “10% to about 20%”). As used herein, unless otherwise indicated or inferred, the term “about” means ± 10% variation of the nominal value of an indicator.

[0043] Throughout this specification, numerical ranges are provided for certain quantities or parameters. It should be understood that these ranges include endpoints and all subranges thereof, including every integer within and between the disclosed ranges. Thus, the range “50 to 80” includes all possible ranges therein (e.g., 51-79, 52-78, 53-77, 54-76, 55-75, 60-70, etc.) and every individual integer from 50 to 80 (e.g., 50, 51, 52, 53, 54, etc.). Where ranges are provided in the form of fractions, percentages, decimals, etc., such ranges similarly include all possible subranges therein and every individual fraction, percentage, decimal, etc., within and between the disclosed ranges. For example, the range “0.1 to 1.0” includes all possible ranges therein (e.g., 0.2 to 0.9, etc.) and every individual 1 / 10 decimal from 0.1 to 1.0 (e.g., 0.1, 0.2, 0.3, 0.4, etc.). Furthermore, all values ​​within a given range can be endpoints of the range it covers (e.g., the range 50-80 includes ranges with endpoints, such as 55-80, 50-75, etc.).

[0044] The term “a / an” refers to one or more of the entities; for example, “medium” refers to one or more media or at least one medium. Thus, the terms “a / an”, “one or more”, and “at least one” are used interchangeably herein. Furthermore, reference to a component by the indefinite article “a or an” does not preclude the possibility of more than one component unless the context clearly requires the presence of one and only one component.

[0045] The verb "comprising / including" and its forms / variations, as used in this specification and claims, are used in a non-limiting sense to mean the articles included following the word, but do not exclude articles not expressly mentioned. The invention may suitably "comprising / including," "consisting of," or "substantially consist of" the steps, elements, and / or reagents described in the claims.

[0046] As used herein, the term “adeno-associated virus” (AAV) refers to a small, replication-defective, non-enveloped virus that infects humans and some other primate species. AAVs consist of a protein shell (often called a “capsid”) surrounding a core containing the viral genome. AAVs are known not to cause disease and elicit a very mild immune response. Gene therapy vectors utilizing AAVs can infect both dividing and dormant cells and can persist in an extrachromosomal state without integrating into the host cell’s genome. These characteristics make AAVs an attractive viral vector for gene therapy. Currently, there are 13 recognized naturally occurring AAV serotypes (AAV1–13) and many variants, including, for example, AAVhu.37 and AAVrh.10. The term “recombinant adeno-associated virus” (rAAV) refers to an AAV engineered to carry a heterologous nucleic acid of interest by deleting all or part of the internal portion of the AAV genome and inserting heterologous nucleic acids of interest between inverted terminal repeat sequences (ITRs). The complete ITR-to-ITR DNA sequence of rAAV is referred to as the “vector genome.”

[0047] Unless otherwise specified, when the terms “between” or “starting from” are used to refer to a range of values, the range includes the specified endpoints. For example, the range “between 1 μM and 10 μM” includes 1 μM, 10 μM, and values ​​greater than 1 μM but less than 10 μM.

[0048] As used herein, the term “recombinant adeno-associated virus particle” or “rAAV particle” refers to a particle containing at least one viral capsid protein that (i) capsidates a nucleic acid, such as a vector genome or a portion thereof, and / or (ii) forms a structure surrounding a core.

[0049] The term “complete” or “complete capsid” in relation to rAAV particles or their capsidated vector genomes refers to capsid particles containing a complete vector genome (i.e., a vector genome containing heterologous nucleic acids of interest flanked by AAV ITRs).

[0050] The term "intermediate" in relation to rAAV particles or their capsidated vector genomes refers to a capsid particle containing a portion of the vector genome, i.e., a complete vector genome smaller in size or length (e.g., measured in total base pairs) than the complete vector genome containing the heterologous nucleic acids of interest flanked by AAV ITRs.

[0051] The term "empty" in rAAV particles refers to capsid particles that do not contain capsidated vector genomes.

[0052] As used herein, the term "inverted terminal repeat sequence" (abbreviated as "ITR") refers to a symmetrical nucleic acid sequence in the adeno-associated virus (AAV) genome required for efficient replication. ITR sequences are located at each end of the AAV DNA genome. ITRs serve as the replication origin for viral DNA synthesis and are essential cis-components for packaging the AAV DNA genome into the vector capsid that generates the rAAV vector.

[0053] The use of the terms “include, include, including,” “have, has, having,” and “contain, contains, or containing” should be understood, including their grammatical equivalents, which are generally open-ended and non-restrictive, e.g., do not exclude additional unlisted elements or steps unless otherwise expressly stated or understood from the context.

[0054] As used herein, the terms “filtration system,” “filtration scheme,” “filter tandem,” “filter chain,” “filter series,” “system,” “scheme,” “tandem,” “chain,” and “series” are used interchangeably and refer to a series of filtration modules or filter types in which rAAV feed material passes through each filter type of the system to produce a final clarified rAAV preparation.

[0055] As used herein, the terms “filtrate,” “fraction,” “elution,” or “flowthrough” refer to all or part of the “feed material,” “cell lysate,” “cell harvest,” or “rAAV preparation” obtained or collected after passing the feed material or cell lysate through a “filter,” “medium,” or “resin.” As used herein, the terms “filtrate,” “fraction,” “elution,” or “flowthrough” also refer to all or part of the obtained filtrate after passing it through a “filter,” “medium,” or “resin.”

[0056] As used herein, the terms “feed material,” “cell lysate,” “cell harvest,” or “rAAV preparation” refer to a suspension, mixture, cell culture environment, or supernatant obtained from an rAAV production host cell culture that produces rAAV, wherein the solution is intended to contain rAAV particles and impurities.

[0057] As used herein, the term "impurity" refers to non-rAAV particles released from the rAAV production host cell culture during rAAV production, including but not limited to cell debris, cell compartments, proteins, peptides, metabolites, and nucleic acids and their fragments. Impurities may also include helper viral particles.

[0058] As used herein, “obtain” or “to acquire” in relation to “filtrate,” “fraction,” “elution,” or “flowthrough” (e.g., filtrate or flowthrough collected after the step of passing cell lysate or previously collected filtrate through or applying it to a filter medium (which may be a pre-filter medium, depth filter, anion exchanger medium, or bioload reduction filter)) means that the fraction or eluent is generated during and up to the end of the step. The fraction “obtained” or “generated” may or may not be collected.

[0059] As used herein, the terms “clarified lysate,” “clarified filtrate,” or “clarified rAAV preparation” refer to a final or final filtrate containing rAAV particles obtained after passing cell lysate or feed material from rAAV production host cell culture through one or more filter media, wherein the final filtrate contains approximately 0%–50% fewer impurities than the cell lysate or feed material.

[0060] As used herein, the term "recombination" can be used to describe, for example, nucleic acid molecules having sequences that are not naturally occurring or sequences created by artificially combining two sequence fragments that are otherwise separated. Such artificial combination can be achieved through chemical synthesis or through artificial manipulation of separated fragments of nucleic acid molecules (e.g., through genetic engineering techniques).

[0061] "Recombinant adeno-associated virus preparation" or "rAAV preparation" refers to a product produced by a method of manufacturing recombinant AAV in host cells (e.g., mammalian or insect cells). In some embodiments, the recombinant AAV preparation comprises a mixture of intact rAAV particles and empty rAAV particles. In some embodiments, the recombinant AAV preparation undergoes one or more downstream operations following an initial upstream operation (e.g., nuclease treatment, filtration to remove host cell impurities, and / or affinity purification using a ligand that binds to the AAV capsid). In some embodiments, the recombinant AAV preparation has been treated with one or more nucleases (including, but not limited to, endonucleases, deoxyribonucleases, and ribonucleases). In some embodiments, the recombinant AAV preparation has been treated with one or more endonucleases. In some embodiments, the recombinant AAV preparation has been treated with one or more endonucleases, including but not limited to benzoase. ® EndoCleave ® Denarase ® OmniCleave ® and ArcticZymes ® .

[0062] As used herein, the term "vector" can refer to a nucleic acid molecule that allows the insertion or insertion of a foreign nucleic acid without impairing the vector's ability to replicate and / or integrate in a host cell. A vector may include nucleic acid sequences that allow it to replicate in a host cell, such as an origin of replication. A vector may also include one or more selectable marker genes and other genetic elements. An expression vector is a vector containing the necessary regulatory sequences to allow the transcription and translation of one or more inserted genes. The term "vector" is also used in a more general sense to refer to a carrier or medium, such as in the case of a viral vector designed to deliver heterologous DNA to target cells or tissues, for example, for gene therapy purposes, such as an AAV vector.

[0063] As used herein, the term "module" refers to an arrangement or system that may include a filter. A module as described herein may further include suitable mechanisms for passing cell lysates or previously obtained filtrates through the filter and / or detecting their passage. Such mechanisms may be pumps, syringes, tubing, feed containers, filtrate collection containers, sensors (including, but not limited to, pressure sensors, conductivity sensors, flux sensors, or combinations thereof).

[0064] As used herein, the terms “filter,” “filter medium,” “filtration medium,” “medium,” etc., refer to a physical structure to which an rAAV preparation is applied to achieve the separation of certain fractions and impurities of the rAAV preparation, such as a resin-filled column or monolithic component or membrane, fibrous or woven fiber structure, etc. For example, an rAAV preparation can be applied to a filter, which can then be washed with one or more solutions to allow rAAV in the preparation to pass through (and collect the rAAV-containing fractions) while preventing impurities and rAAV-free fractions (or vice versa; i.e., allowing impurities and rAAV-free fractions to pass through while preventing rAAV in the preparation). In some embodiments, the separation medium is an anion exchange medium. In some embodiments, the separation medium is a mixed-mode medium that can act as an anion exchange medium. In some embodiments, the separation medium is a column (e.g., particles in a monolithic column or a packed column). In some embodiments, the filter medium is a membrane. The term “medium” typically refers to a substance or substrate, and the term “medium” is typically used in the plural of “medium,” meaning more than one medium. However, it is common in the art to use "medium" and "media" interchangeably. Therefore, references to "media" throughout this specification do not necessarily imply or require more than one "media" unless the context clearly indicates otherwise.

[0065] As used herein, the terms “GC / L bed volume” or “GC / L-BV” or “GC / L membrane volume” or “GC / L-MV” refer to the total concentration of rAAV or adenovirus particles in the filtrate volume loaded onto a filter (e.g., an anion exchange filter or membrane).

[0066] As used herein, the term "conductivity" refers to the ability of a solution, cell lysate, cell harvest, previously obtained filtrate, or feed material to conduct electrical electricity, measured by determining the resistance of the solution between two flat or cylindrical electrodes spaced at a fixed distance. The conductivity of a solution, as used herein, is due to the presence of one or more cations or electrolytes in the solution, including but not limited to H+. - Li + Na + K + NH4 + Ag + Ca 2+ Co(NH3)6 3+ OH - Cl - ,Br - I - NO3 - CH3COO - ClO4 - F - SO4 2- C2O4 2- HC2O4 - HCOO - CO3 2- HSO3 2- and SO3 2-The conductivity of the solution passing through the filter determines whether rAAV will be retained in the filter media or pass through with the filtrate. The conductivity / ionic strength of the filter load (i.e., the preparation to be filtered) is critical, such that adjusting the filter load conductivity to a specific range (optimal conductivity range) allows rAAV to pass through the filter while retaining impurities, including helper viruses (or vice versa). As an example, if the filter load conductivity is above the optimal conductivity range, rAAV can bind to the filter along with impurities and / or helper viruses. On the other hand, if the filter load conductivity is below the optimal conductivity range, impurities and / or helper viruses can also pass through the filter along with rAAV. The optimal conductivity range can vary depending on the specific filter media and solute. For example, for a high ligand density AEX filter (e.g., containing positively charged quaternary amine functional groups), helper viruses can elute at about 40 mS / cm, while rAAV can elute at about 9–12 mS / cm, thus allowing the AEX filter to operate at 36 mS / cm. As described herein, the conductivity of the feed material or previously collected filtrate containing rAAV and impurities can be adjusted (increased or decreased) to prevent the binding of rAAV particles in the feed material, but allow impurities to bind to the filter (or vice versa). As described herein, the conductivity of the feed material or previously collected filtrate can be adjusted by increasing or decreasing the electrolyte or cation or anion content of the feed material or previously collected filtrate. The cation or anion content of the feed material or previously collected filtrate can be increased by adding a suitable ion solution to the feed material or previously collected filtrate. The cation or anion content of the feed material or previously collected filtrate can be decreased by diluting the feed material or previously collected filtrate with a suitable diluent.

[0067] As used herein, the term Dynamic Binding Capacity (DBC) for chromatographic filters or media (e.g., anion adsorption filters, like Q filters) describes the maximum amount of target protein or viral particles (e.g., rAAV particles or adenovirus 5 particles) that can be loaded onto the filter without causing unwanted penetration, as measured under real experimental conditions (operating flow rate, representative impurity matrix).

[0068] Methods for producing AAV

[0069] Methods for producing AAV (including rAAV) are described in this art (see, for example: WO 2023 / 172491 A1 (incorporated herein by reference in its entirety); WO 2020 / 154607 A1 (incorporated herein by reference in its entirety); and WO2022 / 112218 A1 (incorporated herein by reference in its entirety)). Such methods can utilize host cells to produce AAV vectors (including rAAV). In some embodiments, the host cell may contain recombinant nucleic acid molecules, viral vectors (e.g., AAV vectors), or rAAV disclosed herein. The host cell can be suitable for the propagation and / or production of AAV.

[0070] Any known host cell can be used for AAV production. Examples of known host cell types include bacterial cells, yeast cells, insect cells (such as Sf9 cells), and mammalian cells. In some implementations, the host cell can be a cell (or cell line) suitable for producing AAV (e.g., rAAV), such as HeLa cells, Cos-7 cells, HEK293 cells (and HEK293-derived cell lines), AGEI.hn cells, A549 cells, BHK cells, Vero cells, RD cells, ARPE-19 cells, CAP cells, HEK293, PER.C6, NS01, CHO, CV1, VERO, MDCK, BRL3A, W138, or HepG2 cells. In some implementations, stable inducible AAV production cell lines are utilized in the systems and methods described herein, such as doxycycline-induced CAP cells and HEK293 cells as described in WO 2022 / 112218 A1, and HeLa PCL as described in WO2020154607 and WO 2023172491 (which are incorporated herein by reference in their entirety).

[0071] Recombinant nucleic acid molecules or vectors can be delivered into host cell cultures using any suitable method known in the art (e.g., transfection-based methods). In some embodiments, a stable host cell line is utilized having a recombinant nucleic acid molecule or vector inserted into its genome via transfection. Furthermore, stable cell lines can be established and utilized according to methods known in the art, such as those described in Clark, Kidney International, Vol. 61 (2002):S9-S15, and Yuan et al., Human Gene Therapy, May 2011; 22(5):613-24.

[0072] Host cells used for AAV production can be engineered into AAV-producing cells. Therefore, AAV-producing cell lines (PCLs) can be used to generate AAV-producing cell harvests for use in the systems and methods described herein.

[0073] AAV production requires various cellular / viral components. For example, all components used for AAV replication, vector genome packaging, and capsid structural components must be produced to generate AAV particles. The AAV Rep gene encodes four proteins involved in packaging and replication, and the cap gene encodes three structural capsid proteins (called VP1, VP2, and VP3). Wild-type AAV is replication-deficient and requires co-infection of cells with helper viruses (such as herpesviruses or adenoviruses, such as Ad5 viruses) for replication. For example, Ad5 viruses provide Ad5 helper viral functional factors / genes that mediate AAV replication, such as E1a, E1b, E40rf6, E2a, and / or virus-associated (VA) RNA. See, for example, Nayak et al., J Virol. [Journal of Virology] 81.5(2007):2205-12. Recombinant AAV vectors allow the integration of genes of interest or transgenes into viral vectors, enabling the transgenes to be delivered, encoded, and / or expressed via the viral machinery. In some cases, recombinant AAV vectors contain inverted terminal repeat (ITR) sequences that serve as the starting point for replication and / or packaging. In some embodiments, recombinant AAV vectors contain transgenes flanked by ITRs (there is an ITR on either side of the transgene). See, for example, Carter B. Adeno-Associated Virus and AA V Vectors for Gene Delivery, in Gene and Cell Therapy, 4th ed., NS Templeton. 2015, CRC Press.

[0074] AAV PCLs containing one or more of these components required for AAV production can be generated. An exemplary list of AAV components includes (a) nucleic acid sequences containing transgenes (e.g., therapeutic payloads); (b) nucleic acid sequences containing inverted terminal repeat sequences (ITRs) (e.g., one or two ITRs), such that two ITRs are side-attached to one or more additional AAV components (e.g., transgenes); (c) nucleic acid sequences encoding one or more AAV replication and / or packaging proteins (e.g., encoded by AAV rep genes); (d) nucleic acid sequences encoding one or more AAV structural capsid proteins (e.g., encoded by AAV cap genes, such as VP1, VP2, or VP3 proteins); (e) one or more AAV replication and / or packaging proteins; (f) one or more AAV structural capsid proteins; and / or (g) one or more helper viral components, such as Ad5 helper viral components (e.g., E1a, E1b, E40rf6, E2a, and / or VA RNA; or Ad5 helper virus). As used herein, “AAV PCL” or “AAV production cell line” means a cell that contains one or more of the above (a)-(g) and is capable of producing AAV under suitable production conditions known in the art when any necessary one or more auxiliary viral components are provided, such as the cells described herein.

[0075] Any cell line suitable for AAV production can be used as the host cell for AAV production to generate a clarified and purified AAV product for use in the systems and methods described herein, including suitable mammalian and insect cell lines (including Sf9 cells). For example, a mammalian cell line containing one or more components required for AAV production (e.g., PCL derived from any mammalian cell line) can be used in any of the systems and methods described herein. In some embodiments, the systems and methods described herein include culturing mammalian cells, such as human cells, or non-human mammalian cells, such as mammalian PCL, such as human PCL or non-human mammalian PCL. Exemplary cell types include, but are not limited to: BALB / c mouse myeloma line (NSO / 1, ECACC No.: 85110503); human retinal cells (PER.C6 (CruCell, Leiden, The Netherlands)); monkey kidney CV1 line transformed with SV40 (COS-7, ATCC CRL1651); human embryonic kidney line (293 cells or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Virol. [Journal of General Virology], 36:59 (1977)); juvenile hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells + / - DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States of America], 77:4216 (1980)); mouse saturated cells (TM4, Mather, Biol. Reprod.). [Reproductive Biology], 23:243-251 (1980); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1 587); human cervical cancer cells (HeLa, ATCC CCL 2 or HeLa S3, ECACC catalog number 87110901); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human hepatocytes (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annals NY Acad. Sci. [Annals of the New York Academy of Sciences], 383:44-68). (1982)); FS4 cells; human hepatocellular carcinoma line (Hep G2); and / or PCL forms of any cell type described herein.In some implementations, the PCL form of the cell types described herein includes cell types that have been engineered to have one or more components required for AAV production.

[0076] In some embodiments, the systems and methods described herein include culturing HeLa cells (e.g., HeLa production cell lines (PCL), CHO cells (e.g., CHO PCL), Sf9 cells, Sp2 / 0 cells, ELEVECTA™ production cell lines (Cytiva), HEK cells (e.g., HEK PCL, HEK293), CAP cells, AGElhn cells, PER.C6, NS01, COS cells, BHK, CV1, VERO, MDCK, MDBK cells, BRL3A, W138, and HepG2 cells). In some embodiments, the systems and methods described herein include culturing HeLa cells, such as HeLa PCL. In some embodiments, stable induced AAV production cell lines, such as doxycycline-induced CAP cells and HEK293 production cell lines as described in WO 2022 / 112218 and WO 2020154607 and WO Those of the HeLaPCL described in 2023172491 (which is incorporated herein by reference in its entirety) are used in the systems and methods described herein.

[0077] As described above, in some cases, cells will be selected or engineered to contain one or more components required for AAV production (e.g., engineered into PCL). Alternatively or additionally, engineered PCL may include genetic modifications to reduce the expression and / or activity of one or more genes and / or proteins, which increase AAV titers. Exemplary engineered PCLs that can be used in the systems and methods disclosed herein include those described in U.S. Patent Application Publication No. US 2020 / 0325455 A1.

[0078] AAV can be produced using conventional batch production methods or enhanced methods that implement fed-batch and / or perfusion strategies to increase AAV titers for downstream purification according to the methods described herein. Typically, in batch AAV production, AAV PCL is cultured in N-1 culture vessels to achieve high viable cell density. The N-1 cultured cells are then seeded into N culture vessels at a specific seeding density. The seeded cells in the N culture vessels can be cultured under conditions that allow for AAV production. Typically, modified batch methods involve preparing a vessel with a growth medium for the AAV production cell growth phase culture. In some embodiments, the vessel may be a single vessel designed for both growth and production phase cultures, i.e., a “combined growth / production vessel.” This vessel is then seeded with AAV production cells. Perfusion can be initiated in the seeded growth or combined growth / production vessel to begin AAV production cell growth. Once the final cell density target is reached, production phase culture can be initiated. In some embodiments, initiation of the production phase involves infecting the growth phase culture with a helper virus to begin AAV production. AAV production can be initiated by alternative means that do not rely on AAV helper virus infection. Such alternatives include, for example, using triple transfection methods or using production cells with stable integration of the components required for AAV production, such as adenovirus helper viral function, AAV replicase, and capsid genes (e.g., ELEVECTA® (CEVEC) doxycycline-induced AAV production cells and similar systems). The AAV production phase can be maintained, for example, by providing a feed, exchanging the medium for production medium, and / or initiating perfusion to sustain production. The produced AAV can then be harvested using any suitable separation technique. The AAV harvest can then be clarified and purified using the methods described herein.

[0079] In some implementations, AAV is produced using a final perfusion production stage in a production container at a scale of, for example, 2000 L. The production container can be any container suitable for producing AAV at any scale for any culture volume. For example, production containers can be sub-liter, 1 L, 2 L, 5 L, 10 L, 20 L, 50 L, 100 L, 150 L, 200 L, 250 L, 500 L, 1000 L, 1500 L, 2000 L, 2500 L, 3000 L, 3500 L, 4000 L, 4500 L, 5000 L, 5500 L, 6000 L, 6500 L, 7000 L, 7500 L, 8000 L, 8500 L, 9000 L, 9500 L, 10000 L, 10500 L, 11000 L, 11500 L, 12000 L containers or larger.

[0080] In some implementations, the N-stage growth culture used for AAV production can be grown at a rate of at least 5 × 10⁻⁶. 6 The target final production cell density is 1 live cells (vc) / mL. N-stage growth can target any final density suitable for inoculating an AAV bioreactor for the production stage, including, for example, 1 × 10⁻⁶. 6 2 × 10 6 3 × 10 6 4 × 10 6 5 × 10 6 6 × 10 6 7 × 10 6 8 × 10 6 9 × 10 6 10 × 10 6 20 × 10 6 30 × 10 6 40 × 10 6 or up to 50 × 10 6 vc / mL or higher.

[0081] In some embodiments, any pre-production stage culture is carried out at any suitable scale for the cell growth phase of AAV production. For example, any pre-production stage culture can be carried out at a scale from subliter to 6000 L. Therefore, the systems and methods of the present invention can be used in bioreactors with containers of subliter, 1 L, 2 L, 5 L, 10 L, 20 L, 50 L, 100 L, 150 L, 200 L, 250 L, 500 L, 1000 L, 1500 L, 2000 L, 2500 L, 3000 L, 3500 L, 4000 L, 4500 L, 5000 L, 5500 L, or 6000 L for pre-production or growth stage cultures.

[0082] In some embodiments, the production stage culture is carried out at any suitable scale for AAV production. For example, the production stage culture can be carried out at a scale from subliter to 6000 L. Therefore, the systems and methods of the present invention can be used in bioreactors with containers of subliter, 1 L, 2 L, 5 L, 10 L, 20 L, 50 L, 100 L, 150 L, 200 L, 250 L, 500 L, 1000 L, 1500 L, 2000 L, 2500 L, 3000 L, 3500 L, 4000 L, 4500 L, 5000 L, 5500 L, or 6000 L for the production stage culture.

[0083] In some embodiments, the methods described herein further include collecting or harvesting AAV products from production-stage cultures. Standard methods for collecting or separating viral particles can be used, such as, but not limited to, filtration or centrifugation. The collected AAV products can be purified using additional downstream purification processes.

[0084] According to the methods described herein, for example in N culture, AAV titer can be determined, for example, on any one or more days of N culture. An exemplary AAV titer measurement is vector genome copy / cell (GC / cell). GC / cell can be determined by standard methods in the art, such as, but not limited to, dot blot, quantitative PCR or ddPCR, spectroscopic or fluorescence assays. See, for example, Dorange et al., Cell Gene Therapy Insights 4.2(2018): 119-129.

[0085] In some implementations, the methods described herein are capable of producing at least about 1 × 10⁻⁶ cells / year in a production-stage culture, for example. 9 Vector genome (vg) / mL, at least approximately 2 × 10⁻⁶ 9 vg / mL, at least about 3 × 10 9 vg / mL, at least about 4 × 10 9 vg / mL, at least about 5 × 10 9 vg / mL, at least about 6 × 10 9 vg / mL, at least about 7 × 10 9 vg / mL, at least about 8 × 10 9 vg / mL, at least about 9 × 10 9 vg / mL, at least about 1 × 10 10 vg / mL, at least about 2 × 10 10 vg / mL, at least about 3 × 10 10 vg / mL, at least about 4 × 10 10 vg / mL, at least about 5 × 10 10 vg / mL, at least about 6 × 10 10 vg / mL, at least about 7 × 10 10 vg / mL, at least about 8 × 10 10 vg / mL, at least about 9 × 10 10 vg / mL, at least about 1 × 10 11 vg / mL, at least about 2 × 10 11 vg / mL, at least about 3 × 10 11 vg / mL, at least about 4 × 1011 vg / mL, at least about 5 × 10 11 vg / mL, at least about 6 × 10 11 vg / mL, at least about 7 × 10 11 vg / mL, at least approximately 8 × 10 11 vg / mL, at least about 9 × 10 11 vg / mL, at least about 1 × 10 12 vg / mL, at least about 2 × 10 12 vg / mL, at least about 3 × 10 12 vg / mL, at least about 4 × 10 12 vg / mL, at least about 5 × 10 12 AAV titer of vg / mL or higher.

[0086] Clarification method

[0087] Clarifying production cell harvest containing rAAV is a crucial step in removing impurities before subjecting the cell harvest to methods for purifying rAAV. Clarification processes fall into two main categories: (a) primary clarification steps for removing most large particles, whole cells, and cell debris, and (b) secondary clarification steps for removing smaller particles present in the resulting filtrate from primary clarification. Common primary clarification methods include centrifugation, transient flow filtration (TFF), and depth filtration, while common secondary clarification methods include depth filtration and bioburden reduction filters. Depth filters are particularly useful in biopharmaceutical development as a one-off clarification solution. The overall performance of commercially available depth filters is known, as they are effective and comparable at small and pilot-scale operations. However, efficient clarification and recovery of rAAV during scale-up production from high-cell-density cultures of production cell lines are often severely limited by filter clogging and stagnation volumes due to pressure differentials exceeding the capacity of conventional depth filters (i.e., the recommended value of 20–25 psi).

[0088] This disclosure provides improved clarification systems, including a range of different filter types, and methods for using these systems to remove impurities from scaled-up volumes of rAAV containing high-production-cell-density harvests while maintaining industry-standard filtration practices, which can reduce downstream purification costs and time.

[0089] This disclosure provides methods for clarifying cell lysates produced from cell cultures expressing recombinant adeno-associated virus (rAAV) particles, the methods comprising: (a) passing the cell lysates through a pre-filter medium to generate a first filtrate; (b) passing the first filtrate through a depth filter medium to generate a second filtrate; (c) passing the second filtrate through an anion exchanger medium to generate a third filtrate; and (d) passing the third filtrate through a bioload reduction filter to generate clarified cell lysates.

[0090] In some embodiments of the method disclosed herein, the cell lysate is generated from a cell culture expressing rAAV with a cell density of approximately 1 × 10⁻⁶ cells / year. 6 To approximately 2 × 10 7 cells / mL (e.g., approximately 1 × 10⁻⁶ cells / mL) 6 To approximately 2 × 10 6 cells / mL, approximately 2 × 10⁻⁶ 6 To approximately 3 × 10 6 cells / mL, approximately 3 × 10⁻⁶ 6 To approximately 4 × 10 6 cells / mL, approximately 4 × 10⁻⁶ 6 To approximately 5 × 10 6 cells / mL, approximately 5 × 10⁻⁶ 6 From approximately 6 × 10 6 cells / mL, approximately 6 × 10⁻⁶ 6 To approximately 7 × 10 6 cells / mL, approximately 7 × 10⁻⁶ 6 To approximately 8 × 10 6 cells / mL, approximately 8 × 10⁻⁶ 6 From approximately 9 × 10 6 cells / mL, approximately 9 × 10⁻⁶ 6 From approximately 1 × 10 7 cells / mL, approximately 1 × 10⁻⁶ 7 To approximately 2 × 10 7 cells / mL, approximately 2 × 10⁻⁶ 6 To approximately 1 × 10 7 cells / mL, approximately 3 × 10⁻⁶ 6 From approximately 1 × 10 7 cells / mL, approximately 3 × 10⁻⁶ 6 From approximately 9 × 10 6 cells / mL, approximately 4 × 10⁻⁶ 6 To approximately 8 × 10 6 cells / mL, approximately 5 × 10⁻⁶ 6 To approximately 7 × 10 6cells / mL, and including approximately 1 × 10 6 2 × 10 7 (cells / mL and all integers thereof). In some embodiments of the method disclosed herein, the cell lysate is composed of cells with a density of at least about 10⁻⁶ cells / mL. 6 The cell lysate is generated from a cell culture expressing rAAV at a density of at least about 8 × 10⁶ cells / mL. In some embodiments of the method disclosed herein, the cell lysate is generated from a cell culture expressing rAAV with a cell density of at least about 8 × 10⁶ cells / mL. 6 To approximately 2 × 10 7 cells / mL (e.g., approximately 8 × 10⁻⁶ cells / mL) 6 To approximately 8.5 × 10 6 cells / mL, approximately 8.5 × 10⁻⁶ 6 From approximately 9 × 10 6 cells / mL, approximately 9 × 10⁻⁶ 6 To approximately 9.5 × 10 6 cells / mL, approximately 9.5 × 10⁻⁶ 6 To approximately 1 × 10 7 cells / mL, approximately 1 × 10⁻⁶ 7 From approximately 1.5 × 10 7 cells / mL, approximately 1.5 × 10⁻⁶ 7 To approximately 2 × 10 7 cells / mL, approximately 8.5 × 10⁻⁶ 6 From approximately 1.5 × 10 7 cells / mL, approximately 9 × 10⁻⁶ 6 From approximately 1 × 10 7 cells / mL, and including approximately 8 × 10 6 2 × 10 7 (cells / mL and all integers thereof). In some embodiments of the method disclosed herein, the cell lysate is composed of cells with a density equal to or greater than 2 × 10⁻⁶ cells / mL. 7 The cell culture expressing rAAV was produced at a rate of 1 cell / mL.

[0091] In some embodiments of the methods disclosed herein, the cell lysates have a pH of about 7.5 to about 8.0 (e.g., about 7.5 to about 7.6, about 7.6 to about 7.7, about 7.7 to about 7.8, about 7.8 to about 7.9, about 7.9 to about 8.0, about 7.6 to about 7.9, about 7.5 to about 7.7, about 7.6 to about 7.9, and all integers including about 7.5 and about 8.0). In some embodiments of the methods disclosed herein, the cell lysates have a pH of about 7.7 to about 7.9 (e.g., about 7.7 to about 7.8, about 7.8 to about 7.9, and all integers including about 7.7 and about 7.9).

[0092] In some embodiments of the methods disclosed herein, the cell lysate comprises rAAV particles and one or more of the following: cell complexes, cell aggregates, colloidal aggregates, nucleases, nucleic acids, host cell proteins, lysed cell debris, and nucleotide fragments. In some embodiments of the methods disclosed herein, the cell lysate comprises one or more nucleases, including but not limited to endonucleases, deoxyribonucleases, and ribonucleases. In some embodiments of the methods disclosed herein, the cell lysate comprises one or more endonucleases. In some embodiments of the methods disclosed herein, the cell lysate comprises one or more endonucleases, including but not limited to benzoase. ® EndoCleave ® Denarase ® OmniCleave ® and ArcticZymes ® For example, cell lysates can be subjected to one or more nucleases, including but not limited to endonucleases, deoxyribonucleases, and ribonucleases. Similarly, cell lysates can be subjected to one or more endonucleases, including but not limited to benzoase. ® EndoCleave ® Denarase ® OmniCleave ® and ArcticZymes ® .

[0093] In some embodiments of the methods disclosed herein, the clarified cell lysate contains rAAV particles. In some embodiments of the methods disclosed herein, the clarified cell lysate retains at least 80% of the total rAAV particles present in the cell lysate. In some embodiments of the methods disclosed herein, the clarified cell lysate retains ≥ 85% (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) of the total rAAV particles present in the cell lysate.

[0094] In some embodiments of the methods disclosed herein, the cell lysate contains helper viral particles. In some embodiments of the methods disclosed herein, the helper viral particles may be any one of adenovirus particles, herpesvirus particles, and papillomavirus particles. In some embodiments of the methods disclosed herein, the helper herpesvirus particles are herpes simplex virus (HSV) particles, human cytomegalovirus (HCMV) particles, or variants or mutants thereof. In some embodiments of the methods disclosed herein, the helper viral particles are adenovirus particles. In some embodiments of the methods disclosed herein, the helper adenovirus particles are adenovirus serotype 5 (Ad5) particles, adenovirus serotype 12 (Ad12) particles, or variants or mutants thereof. In some embodiments of the methods disclosed herein, the adenovirus particles are Ad5 particles or variants or mutants thereof. In some embodiments of the methods disclosed herein, the papillomavirus particles are human papillomavirus type 16 (HPV-16) particles or variants or mutants thereof.

[0095] In some embodiments of the method disclosed herein, the cell lysate contains Ad5 particles with a density of approximately 1 × 10⁻⁶. 12 To approximately 3 × 10 12 GC / ml (e.g., approximately 1 × 10⁻⁶) 12 From approximately 1.2 × 10 12 GC / ml, approximately 1.2 × 10 12 From approximately 1.4 × 10 12 GC / ml, approximately 1.4 × 10⁻⁶ 12 From approximately 1.6 × 10 12 GC / ml, approximately 1.6 × 10⁻⁶ 12 From approximately 1.8 × 10 12 GC / ml, approximately 1.8 × 10 12 To approximately 2 × 10 12 GC / ml, approximately 2 × 10 12 To approximately 2.2 × 10 12 GC / ml, approximately 2.2 × 10 12From approximately 2.4 × 10 12 GC / ml, approximately 2.4 × 10⁻⁶ 12 From approximately 2.6 × 10 12 GC / ml, approximately 2.6 × 10 12 From approximately 2.8 × 10 12 GC / ml, approximately 2.8 × 10 12 To approximately 3 × 10 12 GC / ml, approximately 1.2 × 10 12 To approximately 2.8 × 10 12 GC / ml, approximately 1.4 × 10⁻⁶ 12 From approximately 2.6 × 10 12 GC / ml, approximately 1.6 × 10⁻⁶ 12 From approximately 2.4 × 10 12 GC / ml, approximately 1.8 × 10 12 To approximately 2.2 × 10 12 GC / ml, and including approximately 1 × 10 12 And about 3 × 10 12 GC / ml and all integers in between).

[0096] In some embodiments of the method disclosed herein, the total amount of Ad5 particles in the filtrate volume loaded onto the anion exchange filter volume is approximately 3 × 10⁻⁶. 16 To approximately 5 × 10 16 GC / L membrane volume (GC / L-MV) (e.g., approximately 3 × 10⁻⁶) 16 To approximately 3.25 × 10 16 GC / L-MV, approximately 3.25 × 10 16 To approximately 3.5 × 10 16 GC / L-MV, approximately 3.5 × 10 16 From approximately 3.75 × 10 16 GC / L-MV, approximately 3.75 × 10 16 To approximately 4 × 10 16 GC / L-MV, approximately 4 × 10 16 To approximately 4.25 × 10 16 GC / L-MV, approximately 4.25 × 10 16 From approximately 4.5 × 10 16 GC / L-MV, approximately 4.5 × 10 16 From approximately 4.75 × 10 16 GC / L-MV, approximately 4.75 × 10 16 To approximately 5 × 1016 GC / L-MV, approximately 3.25 × 10 16 From approximately 4.75 × 10 16 GC / L-MV, approximately 3.5 × 10 16 From approximately 4.25 × 10 16 GC / L-MV, and including approximately 3 × 10 16 Approximately 5 × 10 16 GC / L-MV and all integers in between.

[0097] In some embodiments of the method disclosed herein, the total amount of Ad5 particles in the filtrate volume loaded onto the anion exchange filter is approximately 3 × 10⁻⁶. 16 From approximately 7.25 × 10 16 GC / L-MV (e.g., approximately 3 × 10⁻⁶) 16 To approximately 3.25 × 10 16 GC / L-MV, approximately 3.25 × 10 16 To approximately 3.5 × 10 16 GC / L-MV, approximately 3.5 × 10 16 From approximately 3.75 × 10 16 GC / L-MV, approximately 3.75 × 10 16 To approximately 4 × 10 16 GC / L-MV, approximately 4 × 10 16 From approximately 4.25 × 10 16 GC / L-MV, approximately 4.25 × 10 16 From approximately 4.5 × 10 16 GC / L-MV, approximately 4.5 × 10 16 From approximately 4.75 × 10 16 GC / L-MV, approximately 4.75 × 10 16 To approximately 5 × 10 16 GC / L-MV, approximately 5 × 10 16 To approximately 5.25 × 10 16 GC / L-MV, approximately 5.25 × 10 16 To approximately 5.5 × 10 16 GC / L-MV, approximately 5.5 × 10 16 To approximately 5.75 × 10 16 GC / L-MV, approximately 5.75 × 10 16 From approximately 6 × 10 16 GC / L-MV, approximately 6 × 10 16 To approximately 6.25 × 1016 GC / L-MV, approximately 6.25 × 10 16 To approximately 6.5 × 10 16 GC / L-MV, approximately 6.5 × 10 16 To approximately 6.75 × 10 16 GC / L-MV, approximately 6.75 × 10 16 To approximately 7 × 10 16 GC / L-MV, approximately 7 × 10 16 From approximately 7.25 × 10 16 GC / L-MV, approximately 3.25 × 10 16 To approximately 7 × 10 16 GC / L-MV, approximately 3.5 × 10 16 To approximately 6.75 × 10 16 GC / L-MV, approximately 3.75 × 10 16 To approximately 6.5 × 10 16 GC / L-MV, approximately 4 × 10 16 From approximately 6 × 10 16 GC / L-MV, approximately 4.25 × 10 16 To approximately 5.75 × 10 16 GC / L-MV, approximately 4.5 × 10⁻⁶ 16 To approximately 5.5 × 10 16 GC / L-MV, and including approximately 3 × 10 16 Approximately 7 × 10 16 GC / L-MV and all integers in between.

[0098] In some embodiments of the method disclosed herein, the volume of cell lysate is at least 50 L. In some embodiments of the method disclosed herein, the volume of cell lysate is at least 250 L. In some embodiments of the method disclosed herein, the volume of the cell lysate is between about 50 L and about 250 L (e.g., about 50 L and about 250 L, and including about 50 L and about 60 L, about 60 L and about 70 L, about 70 L and about 80 L, about 80 L and about 90 L, about 90 L and about 100 L, about 100 L and about 120 L, about 120 L and about 150 L, about 150 L and about 170 L, about 170 L and about 200 L, about 200 L and about 220 L, about 220 L and about 250 L, about 60 L and about 220 L, about 70 L and about 200 L, about 80 L and about 170 L, about 90 L and about 150 L and all integers therebetween, and including about 50 L and about 250 L and all integers therebetween).

[0099] In some embodiments of the method disclosed herein, the pre-filter is a particulate filter. In some embodiments of the method disclosed herein, the pre-filter medium includes any one of the following: a pre-filter based on polypropylene fleece, a pre-filter based on absorbent glass fleece material, a pre-filter based on mixed cellulose esters, a pre-filter based on nylon membranes, a pre-filter based on glass and quartz fibers, a filter based on polyvinyl chloride, and a filter based on polytetrafluoroethylene.

[0100] In some embodiments of the methods disclosed herein, the pre-filter medium comprises a polypropylene wool-based pre-filter. In some embodiments of the methods disclosed herein, the polypropylene wool-based pre-filter is any one of Sartopure® PP3, BECO PROTECT PG® pre-filter, and EMD Millipore® polypropylene pre-filter. In some embodiments, the pre-filter medium comprises a pre-filter based on absorbent glass wool material. In some embodiments of the methods disclosed herein, the absorbent glass wool-based pre-filter is any one of Sartopure® PP3 Maxicaps® filter and Sartorius Stedim Biotech™ Sartopure™ filter. In some embodiments of the methods disclosed herein, the pre-filter medium comprises a pre-filter based on mixed cellulose esters. The mixed cellulose ester-based pre-filter may contain nitrocellulose and appropriate amounts of cellulose acetate, acetone, n-butanol, or ethanol. In some embodiments of the methods disclosed herein, the pre-filter based on mixed cellulose esters is any one of Fisherbrand™ mixed cellulose ester membrane, Whatman™ mixed cellulose ester membrane, Advantec® mixed cellulose ester membrane, Sterlitech® nitrated cellulose mixed ester membrane filter, and Immobilon® -NC membrane Triton-free mixed cellulose ester filter.

[0101] In some embodiments of the methods disclosed herein, the pre-filter comprises a nylon membrane-based pre-filter. In some embodiments of the methods disclosed herein, the nylon membrane-based pre-filter is any one of the following: Sterlitech® nylon membrane filter, Hydrofil™ nylon 6.6 membrane filter, PALL 66606 Nylaflo™ nylon membrane filter, Nalgene® Rapid-Flow™ tissue culture filter, and Tisch Scientific® nylon membrane filter. In some embodiments of the methods disclosed herein, the pre-filter comprises a glass and quartz fiber-based pre-filter. In some embodiments of the methods disclosed herein, the glass and quartz fiber-based pre-filter is any one of the following: Advantec® glass and quartz fiber filter and EMD Millipore® glass and quartz fiber filter. In some embodiments of the methods disclosed herein, the pre-filter comprises a polyvinyl chloride (PVC)-based filter. In some embodiments, the PVC-based filter is any one of the following: EMD Millipore® PVC membrane filter, Cytiva GLA-5000™ PVC membrane disc filter, and Durapore® membrane filter. In some embodiments of the methods disclosed herein, the pre-filter comprises a polytetrafluoroethylene (PTFE)-based filter. In some embodiments of the methods disclosed herein, the PTFE-based filter is any one of a Sterlitech® PTFE laminated membrane filter, a Fluoropore™ PTFE membrane filter, an Omnipore™ PTFE membrane filter, an Omnipore™ membrane filter, and a Mitex™ membrane filter.

[0102] In some embodiments of the method disclosed herein, the pre-filter medium has a pore size of about 20 μm to about 75 μm (e.g., about 20 μm to about 25 μm, about 25 μm to about 30 μm, about 30 μm to about 35 μm, about 35 μm to about 40 μm, about 40 μm to about 45 μm, about 45 μm to about 50 μm, about 50 μm to about 55 μm, about 55 μm to about 60 μm, about 60 μm to about 65 μm, about 65 μm to about 70 μm, about 70 μm to about 75 μm, about 25 μm to about 70 μm, about 30 μm to about 65 μm, about 35 μm to about 60 μm, about 40 μm to about 55 μm, and all integers including about 20 μm and about 75 μm and therebetween). In some embodiments of the method disclosed herein, the pre-filter medium has a pore size of about 50 mm.

[0103] In some embodiments of the method disclosed herein, passing cell lysates through a pre-filter medium increases the volumetric capacity of the depth filter by at least 25%. In some embodiments of the method disclosed herein, passing cell lysates through a pre-filter medium increases the volumetric capacity of the depth filter by about 25% to about 50% (e.g., about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 30% to about 50%, about 35% to about 45%, about 35% to about 50%, about 25% to about 45%, and all percentages including about 25% and about 50%). In some embodiments of the method disclosed herein, passing cell lysates through a pre-filter medium increases the filtration capacity of the depth filter by about 30 to about 50 L / m³. 2 (For example, approximately 30 to approximately 32 L / m) 2 Approximately 32 to approximately 34 L / m 2 Approximately 34 to approximately 36 L / m 2 Approximately 36 to approximately 38 L / m 2 Approximately 38 to approximately 40 L / m 2 Approximately 40 to approximately 42 L / m 2 Approximately 42 to approximately 44 L / m 2 Approximately 44 to approximately 46 L / m 2 Approximately 46 to approximately 48 L / m 2 Approximately 48 to approximately 50 L / m 2 Approximately 32 to approximately 48 L / m 2 Approximately 32 to approximately 46 L / m 2 Approximately 34 to approximately 44 L / m 2 Approximately 36 to approximately 42 L / m 2 and including approximately 30 and approximately 50 L / m 2 (and all integers in between).

[0104] In some embodiments of the method disclosed herein, the flow rate of cell lysate in the pre-filter medium is from about 225 to about 925 L / m. 2 h (approximately 225 to approximately 275 L / m) 2 h, approximately 275 to approximately 325 L / m 2 h, approximately 325 to approximately 375 L / m 2 h, approximately 375 to approximately 425 L / m 2 h, approximately 425 to approximately 475 L / m 2 h, approximately 475 to approximately 525 L / m 2 h, approximately 525 to approximately 575 L / m 2 h, approximately 575 to approximately 625 L / m 2 h, approximately 625 to approximately 675 L / m2 h, approximately 675 to approximately 725 L / m 2 h, approximately 725 to approximately 775 L / m 2 h, approximately 775 to approximately 825 L / m 2 h, approximately 825 to approximately 875, approximately 875 to approximately 925 L / m 2 h, approximately 275 to approximately 875 L / m 2 h, approximately 325 to approximately 825 L / m 2 h, approximately 375 to approximately 775 L / m 2 h, approximately 425 to approximately 725 L / m 2 h, approximately 475 to approximately 675 L / m 2 h, approximately 525 to approximately 625 L / m 2 h, and including approximately 250 and approximately 925 L / m 2 h and all integers in between.

[0105] In some embodiments of the method disclosed herein, the pre-filter medium has a concentration of about 300 to about 700 L / m³. 2 (For example, approximately 300 to approximately 350 L / m) 2 Approximately 350 to approximately 400 L / m 2 Approximately 400 to approximately 450 L / m 2 Approximately 450 to approximately 500 L / m 2 Approximately 500 to approximately 550 L / m 2 Approximately 550 to approximately 600 L / m 2 Approximately 600 to approximately 650 L / m 2 Approximately 650 to approximately 700 L / m 2 Approximately 350 to approximately 650 L / m 2 Approximately 400 to approximately 600 L / m 2 Approximately 450 to approximately 650 L / m 2 Approximately 350 to approximately 550 L / m 2 and including approximately 300 and approximately 700 L / m 2The volumetric capacity is approximately 1 to approximately 5 psi (e.g., approximately 1 to approximately 1.5 psi, approximately 1.5 to approximately 2 psi, approximately 2 to approximately 2.5 psi, approximately 2.5 to approximately 3 psi, approximately 3 to approximately 3.5 psi, approximately 3.5 to approximately 4 psi, approximately 4 to approximately 4.5 psi, approximately 4.5 to approximately 5 psi, approximately 1.5 to approximately 4.5 psi, approximately 2 to approximately 4 psi, approximately 2.5 to approximately 3.5 psi, approximately 3 to approximately 5 psi, approximately 2 to approximately 4 psi, approximately 1 to approximately 3 psi, and including approximately 1 and approximately 5 psi and all integers therebetween).

[0106] In some embodiments of the methods disclosed herein, the depth filter medium comprises any one of cellulose-based filter media, glass-based filter media, and acrylic acid-based filter media. In some embodiments of the methods disclosed herein, the depth filter medium comprises 2 to 8 layers of filter media. In some embodiments of the methods disclosed herein, the depth filter further comprises any one of diatomaceous earth (DE) filter aid and silica filter aid. In some embodiments of the methods disclosed herein, the depth filter medium comprises at least one polypropylene fiber pulp, a nonwoven fiber layer, or a combination thereof. In some embodiments of the methods disclosed herein, the depth filter medium further comprises a cationic binder.

[0107] In some embodiments of the methods disclosed herein, the depth filter comprises a cellulose-based filter media. In some embodiments of the methods disclosed herein, the cellulose-based filter media is any one of the following: Sartoclear® depth filter, Seitz® ZD pure cellulose depth filter, EMD Millipore® mixed cellulose ester filter, Millistak+® depth filter, Stax™ mAx depth filter, Allegro™ Connect depth filter, Stax™ disposable depth filter, and Stax™ mAx CF cake filter.

[0108] In some embodiments of the methods disclosed herein, the depth filter comprises a glass-based filter medium. In some embodiments of the methods disclosed herein, the glass-based filter medium is any one of the following: Cytiva® 934-AH glass microfiber filter, Cytiva® EX / THICK glass fiber filter, Sartorius® glass microfiber filter, Sterlitech® glass fiber filter, Merck® glass fiber filter, and borosilicate glass microfiber filter.

[0109] In some embodiments of the methods disclosed herein, the depth filter comprises an acrylic-based filter media. In some embodiments of the methods disclosed herein, the acrylic-based filter media is any of the Millistak+® HC ProPod depth filters.

[0110] In some embodiments of the method disclosed herein, the flow rate of the first filtrate in the depth filter medium is about 50 to about 150 L / m. 2 h (e.g., about 50 to about 75 L / m) 2 h, approximately 75 to approximately 100 L / m 2 h, approximately 100 to approximately 125 L / m 2 h, approximately 125 to approximately 150 L / m 2 h, approximately 75 to approximately 125 L / m 2 h, approximately 100 to approximately 150 L / m 2 h, approximately 75 to approximately 150 L / m 2 h, approximately 50 to approximately 100 L / m 2 h, and including approximately 50 and approximately 150 L / m 2 h and all integers therein). In some embodiments of the method disclosed herein, the volumetric capacity of the depth filter media is approximately 70 to approximately 200 L / m³. 2 (For example, approximately 70 to approximately 100 L / m) 2 Approximately 100 to approximately 125 L / m 2 Approximately 125 to approximately 150 L / m 2 Approximately 150 to approximately 175 L / m 2 Approximately 175 to approximately 200 L / m 2 Approximately 100 to approximately 175 L / m 2 Approximately 125 to approximately 175 L / m 2 Approximately 150 to approximately 200 L / m 2 Approximately 125 to approximately 175 L / m 2 and including approximately 70 and approximately 200 L / m 2 (and all integers therebetween). In some embodiments of the method disclosed herein, the pressure differential in the depth filter medium is between about 1 and about 18 psi (e.g., about 1 to about 3 psi, about 3 to about 6 psi, about 6 to about 9 psi, about 9 to about 12 psi, about 12 to about 15 psi, about 15 to about 18 psi, about 3 to about 15 psi, about 3 to about 9 psi, about 6 to about 12 psi, about 9 to about 15 psi, about 12 to about 18 psi, and including about 1 and about 18 psi and all integers therebetween).

[0111] In some embodiments of the disclosed method, the depth filter medium comprises a first layer of cellulose fibers and a second layer of cellulose, diatomaceous earth (DE) filter aid, and cationic binder. In some embodiments of the disclosed method, the depth filter medium comprises a first layer of nonwoven fibers, a second layer of polypropylene fiber pulp, and third and fourth layers comprising polyacrylic acid fiber pulp, silica filter aid, and cationic binder. In some embodiments of the disclosed method, the depth filter medium comprises six layers of polypropylene fibers and nonwoven fibers, a second layer of cellulose fibers, and a third layer of cellulose, diatomaceous earth (DE) filter aid, and cationic binder.

[0112] In some embodiments of the methods disclosed herein, the anion exchange adsorber medium is any one of a strong AEX medium or an AEX hybrid medium. In some embodiments of the methods disclosed herein, the strong AEX medium is any one of a Sartobind™ Q medium, a Mustang™ Q medium, or a Natrix™ Q medium. As used herein, the term "AEX hybrid medium" refers to a combination of an AEX filter and a non-AEX filter. In some embodiments of the methods disclosed herein, the non-AEX filter is a fine particulate bioburden reduction membrane. As used herein, the term "strong AEX medium" refers to a single AEX filter medium without any other non-AEX filter medium. In some embodiments of the methods disclosed herein, the AEX hybrid medium comprises an AEX chromatographic medium and a polyamide membrane. In some embodiments of the methods disclosed herein, the AEX hybrid medium comprises an AEX chromatographic medium and a polyethersulfone (PES) membrane. In some embodiments of the methods disclosed herein, the AEX chromatographic medium is a quaternary ammonium salt functionalized AEX medium. In some embodiments of the methods disclosed herein, the quaternary ammonium salt functionalized AEX medium is a nonwoven medium. In some embodiments of the methods disclosed herein, the AEX chromatographic medium is any one of 3M™ Polisher ST, Harvest™ RC, or Emphaze™ AEX media.

[0113] In some embodiments of the method disclosed herein, the pore size of the polyamide membrane or PES membrane is about 0.1 to about 0.5 μm (e.g., about 0.1 to about 0.2 μm, about 0.2 to about 0.3 μm, about 0.3 to about 0.4 μm, about 0.4 to about 0.5 μm, about 0.2 to about 0.4 μm, about 0.1 to about 0.3 μm, about 0.3 to about 0.5 μm, and all integers including about 0.1 and about 0.5 μm and between). In some embodiments of the method disclosed herein, the pore size of the polyamide membrane or PES membrane is 0.2 μm. In some embodiments of the method disclosed herein, the flow rate of the second filtrate in the anion adsorber medium is about 50 to about 200 L / m. 2h (e.g., about 50 to about 75 L / m) 2 h, approximately 75 to approximately 100 L / m 2 h, approximately 100 to approximately 125 L / m 2 h, approximately 125 to approximately 150 L / m 2 h, approximately 150 to approximately 175 L / m 2 h, approximately 175 to approximately 200 L / m 2 h, approximately 75 to approximately 175 L / m 2 h, approximately 100 to approximately 150 L / m 2 h, approximately 125 to approximately 175 L / m 2 h, approximately 150 to approximately 200 L / m 2 h, approximately 50 to approximately 100 L / m 2 h, and including approximately 50 and approximately 200 L / m 2 The volumetric capacity of the anion exchange adsorber medium is between approximately 70 and approximately 200 L / m³. In some embodiments of the method disclosed herein, the volumetric capacity of the anion exchange adsorber medium is between approximately 70 and approximately 200 L / m³. 2 (For example, approximately 100 to approximately 120 L / m) 2 Approximately 120 to approximately 130 L / m 2 Approximately 130 to approximately 140 L / m 2 Approximately 140 to approximately 150 L / m 2 Approximately 150 to approximately 160 L / m 2 Approximately 160 to approximately 170 L / m 2 Approximately 170 to approximately 180 L / m 2 Approximately 180 to approximately 190 L / m 2 Approximately 190 to approximately 200 L / m 2 Approximately 120 to approximately 190 L / m 2 Approximately 130 to approximately 180 L / m 2 Approximately 140 to approximately 170 L / m 2 and including approximately 100 and approximately 200 L / m 2The pressure differential of the anion exchanger medium is between about 1 and about 10 psi (e.g., about 1 to about 2 psi, about 2 to about 3 psi, about 3 to about 4 psi, about 4 to about 5 psi, about 5 to about 6 psi, about 6 to about 7 psi, about 7 to about 8 psi, about 8 to about 9 psi, about 9 to about 10 psi, about 2 to about 9 psi, about 3 to about 8 psi, about 4 to about 7 psi, about 5 to about 8 psi, about 6 to about 9 psi, and including about 1 and about 10 psi and all integers therebetween). In some embodiments of the method disclosed herein, the pressure differential of the anion exchanger medium is between about 1 and about 10 psi (e.g., about 1 to about 2 psi, about 2 to about 3 psi, about 3 to about 4 psi, about 4 to about 5 psi, about 5 to about 6 psi, about 6 to about 7 psi, about 7 to about 8 psi, about 8 to about 9 psi, and including about 1 and about 10 psi and all integers therebetween). In some embodiments of the method disclosed herein, the conductivity of the filter load of the anion adsorber medium is between about 16 and about 40 mS / cm (e.g., about 16 to about 20 mS / cm, about 20 to about 25 mS / cm, about 25 to about 30 mS / cm, about 30 to about 35 mS / cm, about 35 to about 40 mS / cm, about 20 to about 35 mS / cm, about 25 to about 40 mS / cm, about 16 to about 30 mS / cm, and all integers including about 16 and about 40 mS / cm and between). In some embodiments of the method disclosed herein, the conductivity of the filter load is from about 18 to about 37 mS / cm (e.g., about 18 to about 20 mS / cm, about 20 to about 22 mS / cm, about 22 to about 24 mS / cm, about 24 to about 26 mS / cm, about 26 to about 28 mS / cm, about 28 to about 30 mS / cm, about 30 to about 32 mS / cm, about 32 to about 34 mS / cm, about 34 to about 37 mS / cm, about 20 to about 34 mS / cm, about 22 to about 32 mS / cm, about 24 to about 30 mS / cm, and all integers including about 18 and about 37 mS / cm and between).

[0114] In some embodiments of the method disclosed herein, the bioburden reduction filter comprises any one of a PVDF-based filter, a polyethersulfone (PES)-based filter, and a polyamide-based filter. In some embodiments of the method disclosed herein, the flow rate of the third filtrate through the bioburden reduction filter is approximately 300 to approximately 700 L / m³. 2 h (e.g., approximately 300 to approximately 350 L / m) 2 h, approximately 350 to approximately 400 L / m 2 h, approximately 400 to approximately 450 L / m 2 h, approximately 450 to approximately 500 L / m 2 h, approximately 500 to approximately 550 L / m 2 h, approximately 550 to approximately 600 L / m 2 h, approximately 600 to approximately 650 L / m 2h, approximately 650 to approximately 700 L / m 2 h, approximately 300 to approximately 500 L / m 2 h, 350 to approximately 650 L / m 2 h, approximately 400 to approximately 600 L / m 2 h, approximately 450 to approximately 550 L / m 2 h, approximately 500 to approximately 700 L / m 2 h, approximately 550 to approximately 650 L / m 2 h, and including approximately 300 and approximately 700 L / m 2 (h and all integers therein). In some embodiments of the method disclosed herein, the volumetric capacity of the bioburden reduction filter is approximately 200 to approximately 750 L / m³. 2 (For example, approximately 200 to approximately 250 L / m) 2 Approximately 250 to approximately 300 L / m 2 Approximately 300 to approximately 350 L / m 2 Approximately 350 to approximately 400 L / m 2 Approximately 400 to approximately 450 L / m 2 Approximately 450 to approximately 500 L / m 2 Approximately 500 to approximately 550 L / m 2 Approximately 550 to approximately 600 L / m 2 Approximately 600 to approximately 650 L / m 2 Approximately 650 to approximately 700 L / m 2 Approximately 700 to approximately 750 L / m 2 Approximately 250 to approximately 700 L / m 2 Approximately 300 to approximately 650 L / m 2 Approximately 350 to approximately 600 L / m 2 Approximately 400 to approximately 550 L / m 2 and including approximately 200 and approximately 750 L / m 2 (and all integers in between). In some embodiments of the method disclosed herein, the differential pressure limit of the bioburden reduction filter is between about 20 and about 25 psi (e.g., 20 to about 21 psi, about 21 to about 22 psi, about 22 to about 23 psi, about 23 to about 24 psi, about 24 to about 25 psi, about 21 to about 24 psi, about 20 to about 23 psi, about 22 to about 25 psi, and including about 20 and about 25 psi and all integers in between).

[0115] In some embodiments of the methods disclosed herein, the bioburden reduction filter comprises a PVDF-based filter. In some embodiments of the methods disclosed herein, the bioburden reduction filter is any one of a Durapore® membrane filter, a Sterlitech® hydrophilic PVDF membrane, a SteriLUX® PVDF membrane, and a Sartorius Microsart™ PVDF membrane. In some embodiments of the methods disclosed herein, the bioburden reduction filter comprises a PES-based filter. In some embodiments of the methods disclosed herein, the PES-based filter is any one of a PVDF-based filter, a Cytiva® PES filter, a Sterlitech® PES filter, an EZFlow® PES membrane disc filter, a Pharmsteri™ PES filter, and a Millipore Express® filter. In some embodiments of the methods disclosed herein, the bioburden reduction filter comprises a polyamide-based filter. In some embodiments of the methods disclosed herein, the polyamide-based filter is any one of a Sartorius® polyamide membrane filter, a Sterlitech® polyamide filter, a POREX® porous polyamide media filter, and a Millipak® Express filter.

[0116] In some embodiments of the method disclosed herein, passing one or more of the cell lysate, the first filtrate, the second filtrate, or the third filtrate through a filter or medium is done manually or using mechanical equipment. In some embodiments of the method disclosed herein, the mechanical equipment is a peristaltic pump.

[0117] In some embodiments of the method disclosed herein, the method includes passing a washing solution through a filter or medium before and / or after passing one or more of the cell lysate, first filtrate, second filtrate, or third filtrate through a filter or medium. In some embodiments of the method disclosed herein, the washing solution may comprise any one of water, a monovalent salt, a divalent salt, a quaternary ammonium salt, a nonionic surfactant, or a combination thereof.

[0118] In some embodiments of the method disclosed herein, the method includes passing an equilibration buffer through a pre-filter medium, and then passing cell lysates through the pre-filter medium. In some embodiments of the method disclosed herein, the equilibration buffer is a nonionic buffer. In some embodiments, the equilibration buffer comprises NaCl, (NH4)2SO4, Na2SO4, KCl, CH3COONH4, or combinations thereof. In some embodiments, the equilibration buffer comprises NaCl. Any of a variety of equilibration solutions may be used according to the method disclosed herein. In some embodiments of the method disclosed herein, the pH and ionic strength of the buffer equilibration solution are selected based on the characteristics of the viral capsid preparation and / or the type of anion exchange medium used.

[0119] In some embodiments of the methods disclosed herein, the equilibration buffer contains NaCl at a concentration of about 100 mmol (mM) to about 400 mM (e.g., about 100 mM to about 150 mM, about 150 mM to about 200 mM, about 200 mM to about 250 mM, about 250 mM to about 300 mM, about 300 mM to about 350 mM, about 350 mM to about 400 mM, about 150 mM to about 350 mM, about 200 mM to about 300 mM, about 250 mM to about 350 mM, and all integers including about 100 mM and about 400 mM and between). In some embodiments, the equilibration solution contains NaCl at a concentration of about 350 mM.

[0120] In some embodiments of the method disclosed herein, the equilibration solution further comprises Tris. In some embodiments of the method disclosed herein, the equilibration solution comprises Tris at a concentration of about 10 mM to about 50 mM (e.g., about 10 mM to about 15 mM, about 15 mM to about 20 mM, about 20 mM to about 25 mM, about 25 mM to about 30 mM, about 30 mM to about 35 mM, about 35 mM to about 40 mM, about 40 mM to about 45 mM, about 45 mM to about 50 mM, about 15 mM to about 45 mM, about 20 mM to about 40 mM, about 25 mM to about 35 mM, and all integers including about 10 mM and about 50 mM). In some embodiments of the method disclosed herein, the equilibration solution comprises Tris at a concentration of about 20 mM.

[0121] In some embodiments of the method disclosed herein, the equilibrium solution further comprises a nonionic surfactant. In some embodiments, the nonionic surfactant may be any of a fatty alcohol, ether, ester, or block polymer. In some embodiments of the method disclosed herein, the nonionic surfactant may be poloxamer. In some embodiments, the poloxamer may be any of poloxamer 188™, poloxamer 237™, poloxamer 338™, and poloxamer 407™. In some embodiments of the method disclosed herein, the equilibration solution comprises poloxamer 188™ at a concentration of about 0.0005% (w / v) to about 0.01% (w / v) (e.g., about 0.0005% (w / v) to about 0.0006% (w / v), about 0.0006% (w / v) to about 0.0007% (w / v), about 0.0007% (w / v) to about 0.0008% (w / v), about 0.0008% (w / v) to about 0.0009% (w / v), about 0.0009% (w / v) (approximately 0.001% (w / v), approximately 0.001% (w / v) to approximately 0.005% (w / v), approximately 0.005% (w / v) to approximately 0.01% (w / v), approximately 0.0006% (w / v) to approximately 0.005% (w / v), approximately 0.0007% (w / v) to approximately 0.0009% (w / v), approximately 0.0007% (w / v) to approximately 0.005% (w / v), and including approximately 0.0005% (w / v) and approximately 0.01% (w / v) and all percentages therebetween). In some embodiments of the method disclosed herein, the equilibrium solution contains poloxamer 188 at a concentration of approximately 0.001% (w / v).

[0122] In some embodiments of the methods disclosed herein, the equilibration solution has a pH of about 7.0 to about 9.0 (e.g., about 7.0 to about 7.5, about 7.5 to about 8.0, about 8.0 to about 8.5, about 8.5 to about 9.0, about 7.5 to about 8.5, about 7.0 to about 8.0, about 8.0 to about 9.0, and all integers including about 7.0 and about 9.0). In some embodiments of the methods disclosed herein, the equilibration solution has a pH of about 8.0. As a non-limiting example, in some embodiments, the equilibration solution is 20 mM Tris, 350 mM NaCl, and 0.001% (w / v) poloxamer 188.

[0123] In some embodiments, the method disclosed herein further includes collecting a clarified lysate generated from a bioburden reduction filter. In some embodiments, the method disclosed herein further includes detecting the presence of one or more of the following in the collected clarified lysate: cell complexes, cell aggregates, colloidal aggregates, nucleases, nucleic acids, host cell proteins, lysed cell debris, and nucleotide fragments.

[0124] In some embodiments of the method disclosed herein, the amount of impurities with a size ≥ 1 mM to < 50 mM in the clarified cell lysate is ≤ 50% compared to the cell lysate before passing through the pre-filter medium. In some embodiments of the method disclosed herein, the amount of impurities with a size ≥ 50 mM in the clarified cell lysate is ≤ 50% compared to the cell lysate before passing through the pre-filter medium.

[0125] Clarification System

[0126] This disclosure also provides a system for clarifying cell lysates produced from cell cultures expressing recombinant adeno-associated virus (rAAV) particles, the system comprising: (a) a first module including a pre-filter medium that filters the cell lysates to remove particulate matter ≥ 50 μm in size from the cell lysates to generate a first filtrate; (b) a second module including a depth filter medium that filters the first filtrate to remove particulate matter ≥ 1 μm to < 50 μm (e.g., 1 μm to 5 μm, 5 μm to 10 μm, 10 μm to 20 μm, 30 μm to 40 μm, 40 μm to 49.9 μm, 5 μm to 49.9 μm, 10 μm to 30 μm, 20 μm to 40 μm, and all integers including 1 μm and 49.9 μm and between) to generate a second filtrate; (c) The third module includes an anion exchanger medium that filters the second filtrate to remove adenovirus particles from the second filtrate to generate a third filtrate; and (d) the fourth module includes a bioload reduction filter that filters the third filtrate to remove microbial contaminants from the third filtrate to generate a clarified cell lysate.

[0127] In some embodiments of the system disclosed herein, cell lysates are generated from cell cultures expressing rAAV at a cell density of approximately 1 × 10⁻⁶ cells / year. 6 To approximately 2 × 10 7 cells / mL (e.g., approximately 1 × 10⁻⁶ cells / mL) 6 To approximately 2 × 10 6 cells / mL, approximately 2 × 10⁻⁶ 6 To approximately 3 × 10 6 cells / mL, approximately 3 × 10⁻⁶ 6 To approximately 4 × 10 6 cells / mL, approximately 4 × 10⁻⁶ 6 To approximately 5 × 10 6 cells / mL, approximately 5 × 10⁻⁶ 6 From approximately 6 × 106 cells / mL, approximately 6 × 10⁻⁶ 6 To approximately 7 × 10 6 cells / mL, approximately 7 × 10⁻⁶ 6 To approximately 8 × 10 6 cells / mL, approximately 8 × 10⁻⁶ 6 From approximately 9 × 10 6 cells / mL, approximately 9 × 10⁻⁶ 6 From approximately 1 × 10 7 cells / mL, approximately 1 × 10⁻⁶ 7 To approximately 2 × 10 7 cells / mL, approximately 2 × 10⁻⁶ 6 To approximately 1 × 10 7 cells / mL, approximately 3 × 10⁻⁶ 6 From approximately 1 × 10 7 cells / mL, approximately 3 × 10⁻⁶ 6 From approximately 9 × 10 6 cells / mL, approximately 4 × 10⁻⁶ 6 To approximately 8 × 10 6 cells / mL, approximately 5 × 10⁻⁶ 6 To approximately 7 × 10 6 cells / mL, and including approximately 1 × 10 6 2 × 10 7 (cells / mL and all integers thereof). In some embodiments of the system disclosed herein, the cell lysate is composed of cells with a density of at least about 10⁻⁶ cells / mL. 6 The cell lysate is generated from a cell culture expressing rAAV at a density of at least about 8 × 10⁶ cells / mL. In some embodiments of the system disclosed herein, the cell lysate is generated from a cell culture expressing rAAV with a cell density of at least about 8 × 10⁶ cells / mL. 6 To approximately 2 × 10 7 cells / mL (e.g., approximately 8 × 10⁻⁶ cells / mL) 6 To approximately 8.5 × 10 6 cells / mL, approximately 8.5 × 10⁻⁶ 6 From approximately 9 × 10 6 cells / mL, approximately 9 × 10⁻⁶ 6 To approximately 9.5 × 10 6 cells / mL, approximately 9.5 × 10⁻⁶ 6 To approximately 1 × 10 7 cells / mL, approximately 1 × 10⁻⁶ 7 From approximately 1.5 × 10 7 cells / mL, approximately 1.5 × 10⁻⁶ 7 To approximately 2 × 107 cells / mL, approximately 8.5 × 10⁻⁶ 6 From approximately 1.5 × 10 7 cells / mL, approximately 9 × 10⁻⁶ 6 From approximately 1 × 10 7 cells / mL, and including approximately 8 × 10 6 2 × 10 7 (cells / mL and all integers thereof).

[0128] In some embodiments of the system disclosed herein, the cell lysate has a pH of about 7.5 to about 8.0 (e.g., about 7.5 to about 7.6, about 7.6 to about 7.7, about 7.7 to about 7.8, about 7.8 to about 7.9, about 7.9 to about 8.0, about 7.6 to about 7.9, about 7.5 to about 7.7, about 7.6 to about 7.9, and all integers including about 7.5 and about 8.0). In some embodiments of the system disclosed herein, the cell lysate has a pH of about 7.7 to about 7.9 (e.g., about 7.8 to about 7.8, about 7.8 to about 7.9, and all integers including about 7.7 and about 7.9).

[0129] In some embodiments of the system disclosed herein, the helper viral particles are adenovirus particles. In some embodiments of the system disclosed herein, the adenovirus particles are Ad5 particles. In some embodiments of the system disclosed herein, the cell lysate contains Ad5 particles with a density of approximately 1 × 10⁻⁶. 12 To approximately 3 × 10 12 GC / ml (e.g., approximately 1 × 10⁻⁶) 12 From approximately 1.2 × 10 12 GC / ml, approximately 1.2 × 10 12 From approximately 1.4 × 10 12 GC / ml, approximately 1.4 × 10⁻⁶ 12 From approximately 1.6 × 10 12 GC / ml, approximately 1.6 × 10⁻⁶ 12 From approximately 1.8 × 10 12 GC / ml, approximately 1.8 × 10 12 To approximately 2 × 10 12 GC / ml, approximately 2 × 10 12 To approximately 2.2 × 10 12 GC / ml, approximately 2.2 × 10 12 From approximately 2.4 × 10 12 GC / ml, approximately 2.4 × 10⁻⁶ 12 From approximately 2.6 × 10 12GC / ml, approximately 2.6 × 10⁻⁶ 12 From approximately 2.8 × 10 12 GC / ml, approximately 2.8 × 10 12 To approximately 3 × 10 12 GC / ml, approximately 1.2 × 10 12 From approximately 2.8 × 10 12 GC / ml, approximately 1.4 × 10⁻⁶ 12 From approximately 2.6 × 10 12 GC / ml, approximately 1.6 × 10⁻⁶ 12 From approximately 2.4 × 10 12 GC / ml, approximately 1.8 × 10 12 To approximately 2.2 × 10 12 GC / ml, and including approximately 1 × 10⁻⁶ 12 And about 3 × 10 12 GC / ml and all integers in between).

[0130] In some embodiments of the system disclosed herein, the total amount of Ad5 particles in the filtrate volume loaded onto the anion exchange filter is approximately 3 × 10⁻⁶. 16 To approximately 5 × 10 16 GC / L-MV (e.g., approximately 3 × 10⁻⁶) 16 To approximately 3.25 × 10 16 GC / L-MV, approximately 3.25 × 10 16 To approximately 3.5 × 10 16 GC / L-MV, approximately 3.5 × 10 16 From approximately 3.75 × 10 16 GC / L-MV, approximately 3.75 × 10 16 To approximately 4 × 10 16 GC / L-MV, approximately 4 × 10 16 From approximately 4.25 × 10 16 GC / L-MV, approximately 4.25 × 10 16 From approximately 4.5 × 10 16 GC / L-MV, approximately 4.5 × 10 16 From approximately 4.75 × 10 16 GC / L-MV, approximately 4.75 × 10⁻⁶ 16 To approximately 5 × 10 16 GC / L-MV, approximately 3.25 × 10 16 From approximately 4.75 × 10 16 GC / L-MV, approximately 3.5 × 1016 From approximately 4.25 × 10 16 GC / L-MV, and including approximately 3 × 10 16 Approximately 5 × 10 16 GC / L-MV and all integers in between.

[0131] In some embodiments of the system disclosed herein, the total amount of Ad5 particles in the filtrate volume loaded onto the anion exchange filter is approximately 3 × 10⁻⁶. 16 From approximately 7.25 × 10 16 GC / L-MV (e.g., approximately 3 × 10⁻⁶) 16 To approximately 3.25 × 10 16 GC / L-MV, approximately 3.25 × 10 16 To approximately 3.5 × 10 16 GC / L-MV, approximately 3.5 × 10 16 From approximately 3.75 × 10 16 GC / L-MV, approximately 3.75 × 10 16 To approximately 4 × 10 16 GC / L-MV, approximately 4 × 10 16 From approximately 4.25 × 10 16 GC / L-MV, approximately 4.25 × 10 16 From approximately 4.5 × 10 16 GC / L-MV, approximately 4.5 × 10 16 From approximately 4.75 × 10 16 GC / L-MV, approximately 4.75 × 10 16 To approximately 5 × 10 16 GC / L-MV, approximately 5 × 10 16 To approximately 5.25 × 10 16 GC / L-MV, approximately 5.25 × 10 16 To approximately 5.5 × 10 16 GC / L-MV, approximately 5.5 × 10 16 To approximately 5.75 × 10 16 GC / L-MV, approximately 5.75 × 10 16 From approximately 6 × 10 16 GC / L-MV, approximately 6 × 10 16 To approximately 6.25 × 10 16 GC / L-MV, approximately 6.25 × 10 16 To approximately 6.5 × 10 16 GC / L-MV, approximately 6.5 × 1016 To approximately 6.75 × 10 16 GC / L-MV, approximately 6.75 × 10 16 To approximately 7 × 10 16 GC / L-MV, approximately 7 × 10 16 From approximately 7.25 × 10 16 GC / L-MV, approximately 3.25 × 10 16 To approximately 7 × 10 16 GC / L-MV, approximately 3.5 × 10 16 To approximately 6.75 × 10 16 GC / L-MV, approximately 3.75 × 10 16 To approximately 6.5 × 10 16 GC / L-MV, approximately 4 × 10 16 From approximately 6 × 10 16 GC / L-MV, approximately 4.25 × 10 16 To approximately 5.75 × 10 16 GC / L-MV, approximately 4.5 × 10⁻⁶ 16 To approximately 5.5 × 10 16 GC / L-MV, and including approximately 3 × 10 16 Approximately 7.25 × 10 16 GC / L-MV and all integers in between.

[0132] In some embodiments of the system disclosed herein, the volume of cell lysate is at least 50 L. In some embodiments of the system disclosed herein, the volume of cell lysate is at least 250 L. In some embodiments of the system disclosed herein, the volume of the cell lysate is from about 50 L to about 250 L (e.g., about 50 L and about 250 L, and including about 50 L and about 60 L, about 60 L and about 70 L, about 70 L and about 80 L, about 80 L and about 90 L, about 90 L and about 100 L, about 100 L and about 120 L, about 120 L and about 150 L, about 150 L and about 170 L, about 170 L and about 200 L, about 200 L and about 220 L, about 220 L and about 250 L, about 60 L and about 220 L, about 70 L and about 200 L, about 80 L and about 170 L, about 90 L and about 150 L and all integers therebetween, and including about 50 L and about 250 L and all integers therebetween).

[0133] In some embodiments of the system disclosed herein, the pre-filter medium is any one of polypropylene fleece-based pre-filters, pre-filters based on absorbent glass fleece materials, mixed cellulose esters, nylon membrane pre-filters, glass and quartz fiber pre-filters, polyvinyl chloride, and polytetrafluoroethylene.

[0134] In some embodiments of the system disclosed herein, the pre-filter media comprises a polypropylene wool-based pre-filter. In some embodiments of the system disclosed herein, the polypropylene wool-based pre-filter is any one of Sartopure® PP3, BECO PROTECT PG® pre-filter, and EMD Millipore® polypropylene pre-filter. In some embodiments of the system disclosed herein, the pre-filter media comprises a pre-filter based on absorbent glass wool material. In some embodiments of the system disclosed herein, the absorbent glass wool-based pre-filter is any one of Sartopure® PP3Maxicaps® filter and Sartorius Stedim Biotech™ Sartopure™ filter. In some embodiments of the system disclosed herein, the pre-filter media comprises a pre-filter based on mixed cellulose esters. The mixed cellulose ester-based pre-filter may contain nitrocellulose and appropriate amounts of cellulose acetate, acetone, n-butanol, or ethanol. In some embodiments of the system disclosed herein, the pre-filter based on mixed cellulose esters is any one of Fisherbrand™ mixed cellulose ester membrane, Whatman™ mixed cellulose ester membrane, Advantec® mixed cellulose ester membrane, Sterlitech® nitrated cellulose mixed ester membrane filter, and Immobilon® -NC membrane without Triton mixed cellulose ester filter.

[0135] In some embodiments of the system disclosed herein, the pre-filter includes a nylon membrane-based pre-filter. In some embodiments of the system disclosed herein, the nylon membrane-based pre-filter is any one of the following: Sterlitech® nylon membrane filter, Hydrofil™ nylon 6.6 membrane filter, PALL 66606 Nylaflo™ nylon membrane filter, Nalgene® Rapid-Flow™ tissue culture filter, and Tisch Scientific® nylon membrane filter. In some embodiments of the system disclosed herein, the pre-filter includes a glass and quartz fiber-based pre-filter. In some embodiments of the system disclosed herein, the glass and quartz fiber-based pre-filter is any one of the following: Advantec® glass and quartz fiber filter and EMD Millipore® glass and quartz fiber filter. In some embodiments of the system disclosed herein, the pre-filter includes a polyvinyl chloride (PVC)-based filter. In some embodiments of the system disclosed herein, the PVC-based filter is any one of the following: EMD Millipore® PVC membrane filter, Cytiva GLA-5000™ PVC disc filter, and Durapore® membrane filter. In some embodiments of the system disclosed herein, the pre-filter includes a polytetrafluoroethylene (PTFE)-based filter. In some embodiments of the system disclosed herein, the PTFE-based filter is any one of a Sterlitech® PTFE laminated membrane filter, a Fluoropore™ PTFE membrane filter, an Omnipore™ PTFE membrane filter, an Omnipore™ membrane filter, and a Mitex™ membrane filter.

[0136] In some embodiments of the system disclosed herein, the pre-filter medium has a pore size of about 20 μm to about 75 μm (e.g., about 20 μm to about 25 μm, about 25 μm to about 30 μm, about 30 μm to about 35 μm, about 35 μm to about 40 μm, about 40 μm to about 45 μm, about 45 μm to about 50 μm, about 50 μm to about 55 μm, about 55 μm to about 60 μm, about 60 μm to about 65 μm, about 65 μm to about 70 μm, about 70 μm to about 75 μm, about 25 μm to about 70 μm, about 30 μm to about 65 μm, about 35 μm to about 60 μm, about 40 μm to about 55 μm, and all integers including about 20 μm and about 75 μm and therebetween). In some embodiments of the system disclosed herein, the pre-filter medium has a pore size of 50 μm.

[0137] In some embodiments of the system disclosed herein, the depth filter medium is any one of cellulose-based, glass-based, and acrylic-based filter media. In some embodiments of the system disclosed herein, the depth filter medium comprises 2-8 layers of filter media. In some embodiments of the system disclosed herein, the depth filter further comprises any one of diatomaceous earth (DE) filter aid and silica filter aid. In some embodiments of the system disclosed herein, the depth filter medium comprises at least one polypropylene fiber pulp, a nonwoven fiber layer, or a combination thereof. In some embodiments of the system disclosed herein, the depth filter medium further comprises a cationic binder.

[0138] In some embodiments of the system disclosed herein, the depth filter medium comprises a first layer of cellulose fibers and a second layer of cellulose, diatomaceous earth (DE) filter aid, and cationic binder. In some embodiments of the system disclosed herein, the depth filter medium comprises a first layer of cellulose fibers and a second layer of cellulose, diatomaceous earth (DE) filter aid, and cationic binder; the depth filter medium comprises a first layer of nonwoven fibers, a second layer of polypropylene fiber pulp, and third and fourth layers of polyacrylic acid fiber pulp, silica filter aid, and cationic binder. In some embodiments of the system disclosed herein, the depth filter medium comprises six layers of polypropylene fibers and nonwoven fibers, a second layer of cellulose fibers, and a third layer of cellulose, diatomaceous earth (DE) filter aid, and cationic binder.

[0139] In some embodiments of the system disclosed herein, the depth filter comprises a cellulose-based filter media. In some embodiments of the system disclosed herein, the cellulose-based filter media is any one of the following: Sartoclear® depth filter, Seitz® ZD pure cellulose depth filter, EMD Millipore® mixed cellulose ester filter, Millistak+® depth filter, Stax™ mAx depth filter, Allegro™ Connect depth filter, Stax™ disposable depth filter, and Stax™ mAx CF cake filter.

[0140] In some embodiments of the system disclosed herein, the depth filter includes a glass-based filter media. In some embodiments of the system disclosed herein, the glass-based filter media is any one of the following: Cytiva® 934-AH glass microfiber filter, Cytiva® EX / THICK glass fiber filter, Sartorius® glass microfiber filter, Sterlitech® glass fiber filter, Merck® glass fiber filter, and borosilicate glass microfiber filter.

[0141] In some embodiments of the system disclosed herein, the depth filter comprises an acrylic-based filter media. In some embodiments of the system disclosed herein, the acrylic-based filter media is Millistak+. ® HC Pro Pod Deep Filter, Versapor ® Acrylic copolymer membrane disc filters and Minisart with an acrylic-based MBS housing ® Any of the filters.

[0142] In some embodiments of the system disclosed herein, the anion exchange adsorber medium is any one of a strong AEX medium or a mixed AEX medium. In some embodiments of the system disclosed herein, the strong AEX medium is any one of a Sartobind Q medium, a Mustang Q medium, or a Natrix Q medium. In some embodiments of the system disclosed herein, the mixed AEX medium comprises an AEX chromatographic medium and a polyamide membrane. In some embodiments of the system disclosed herein, the mixed AEX medium comprises an AEX chromatographic medium and a polyethersulfone (PES) membrane. In some embodiments of the system disclosed herein, the AEX chromatographic medium is a quaternary ammonium salt functionalized AEX medium. In some embodiments of the system disclosed herein, the quaternary ammonium salt functionalized AEX medium is a nonwoven medium. In some embodiments of the system disclosed herein, the AEX chromatographic medium is any one of a Harvest RC medium or an Emphaze AEX medium. In some embodiments of the system disclosed herein, the pore size of the polyamide membrane or PES membrane is between about 0.1 and about 0.5 μm (e.g., about 0.1 to about 0.2 μm, about 0.2 to about 0.3 μm, about 0.3 to about 0.4 μm, about 0.4 to about 0.5 μm, about 0.2 to about 0.4 μm, about 0.1 to about 0.3 μm, about 0.3 to about 0.5 μm, and all integers including about 0.1 and about 0.5 μm and between). In some embodiments of the system disclosed herein, the pore size of the polyamide membrane or PES membrane is 0.2 μm. In some embodiments of the system disclosed herein, the bioburden reduction filter can be any of a PVDF-based filter, a PES-based filter, and a polyamide-based filter.

[0143] In some embodiments of the systems disclosed herein, the bioburden reduction filter includes a PVDF-based filter. In some embodiments of the systems disclosed herein, the bioburden reduction filter is any one of a Durapore® membrane filter, a Sterlitech® hydrophilic PVDF membrane, a SteriLUX® PVDF membrane, and a Sartorius Microsart™ PVDF membrane. In some embodiments of the systems disclosed herein, the bioburden reduction filter includes a PES-based filter. In some embodiments of the systems disclosed herein, the PES-based filter is any one of a PVDF-based filter, a Cytiva® PES filter, a Sterlitech® PES filter, an EZFlow® PES membrane disc filter, a Pharmsteri™ PES filter, and a Millipore Express® filter. In some embodiments of the systems disclosed herein, the bioburden reduction filter includes a polyamide-based filter. In some embodiments of the systems disclosed herein, the polyamide-based filter is a Sartorius® polyamide membrane filter, a Sterlitech® polyamide filter, a POREX® porous polyamide media, and a Millipak filter. ® Any of the Express filters.

[0144] Filter combination used in the clarification methods and systems of this disclosure

[0145] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polypropylene fleece-based filter, the depth filter comprises 2 to 8 layers of acrylic acid-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a PVDF-based filter.

[0146] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a pre-filter based on an absorbent glass wool material, the depth filter comprises 2 to 8 layers of acrylic-based filter media, the anion exchange adsorbent medium is an AEX hybrid medium, and the bioburden reduction filter is a PVDF-based filter.

[0147] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a pre-filter based on mixed cellulose esters, the depth filter comprises 2 to 8 layers of acrylic acid-based filter media, the anion exchange adsorbent media is an AEX mixed media, and the bioburden reduction filter is a PVDF-based filter.

[0148] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a nylon membrane-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic-based filter media, the anion exchange adsorbent medium is an AEX hybrid medium, and the bioburden reduction filter is a PVDF-based filter.

[0149] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a glass and quartz fiber-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a PVDF-based filter.

[0150] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polyvinyl chloride-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic acid-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a PVDF-based filter.

[0151] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polytetrafluoroethylene-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic acid-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a PVDF-based filter.

[0152] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polypropylene fleece-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a PVDF-based filter.

[0153] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a pre-filter based on an absorbent glass wool material, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion adsorbent medium is an AEX mixed medium, and the bioburden reduction filter is a PVDF-based filter.

[0154] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a pre-filter based on mixed cellulose esters, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is an AEX mixed media, and the bioburden reduction filter is a PVDF-based filter.

[0155] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a nylon membrane-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based depth filter medium, the anion exchange adsorbent medium is an AEX hybrid medium, and the bioburden reduction filter is a PVDF-based filter.

[0156] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a glass and quartz fiber-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a PVDF-based filter.

[0157] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polyvinyl chloride-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a PVDF-based filter.

[0158] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polytetrafluoroethylene-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a PVDF-based filter.

[0159] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polypropylene fleece-based pre-filter, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a PVDF-based filter.

[0160] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a pre-filter based on an absorbent glass wool material, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent medium is an AEX hybrid medium, and the bioburden reduction filter is a PVDF-based filter.

[0161] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a pre-filter based on mixed cellulose esters, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent media is an AEX mixed media, and the bioburden reduction filter is a PVDF-based filter.

[0162] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a nylon membrane-based pre-filter, the depth filter comprises 2 to 8 layers of glass-based depth filter medium, the anion exchange adsorbent medium is an AEX hybrid medium, and the bioburden reduction filter is a PVDF-based filter.

[0163] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a glass and quartz fiber-based pre-filter, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a PVDF-based filter.

[0164] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polyvinyl chloride-based pre-filter, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a PVDF-based filter.

[0165] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polytetrafluoroethylene-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PVDF-based filter.

[0166] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polypropylene fleece-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic acid-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PVDF-based filter.

[0167] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a pre-filter based on an absorbent glass wool material, the depth filter comprises 2 to 8 layers of acrylic-based filter media, the anion exchange adsorbent medium is a strong AEX medium, and the bioburden reduction filter is a PVDF-based filter.

[0168] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a pre-filter based on mixed cellulose esters, the depth filter comprises 2 to 8 layers of acrylic acid-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PVDF-based filter.

[0169] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a nylon membrane-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PVDF-based filter.

[0170] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a glass and quartz fiber-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PVDF-based filter.

[0171] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polyvinyl chloride-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic acid-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PVDF-based filter.

[0172] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polytetrafluoroethylene-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic acid-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PVDF-based filter.

[0173] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polypropylene fleece-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PVDF-based filter.

[0174] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a pre-filter based on an absorbent glass wool material, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion adsorbent medium is a strong AEX medium, and the bioburden reduction filter is a PVDF-based filter.

[0175] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a pre-filter based on mixed cellulose esters, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PVDF-based filter.

[0176] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a nylon membrane-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based depth filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PVDF-based filter.

[0177] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a glass and quartz fiber-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PVDF-based filter.

[0178] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polyvinyl chloride-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PVDF-based filter.

[0179] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polytetrafluoroethylene-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PVDF-based filter.

[0180] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polypropylene fleece-based pre-filter, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PVDF-based filter.

[0181] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a pre-filter based on an absorbent glass wool material, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent medium is a strong AEX medium, and the bioburden reduction filter is a PVDF-based filter.

[0182] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a pre-filter based on mixed cellulose esters, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PVDF-based filter.

[0183] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a nylon membrane-based pre-filter, the depth filter comprises 2 to 8 layers of glass-based depth filter medium, the anion exchange adsorbent medium is a strong AEX medium, and the bioburden reduction filter is a PVDF-based filter.

[0184] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a glass and quartz fiber-based pre-filter, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PVDF-based filter.

[0185] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polyvinyl chloride-based pre-filter, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PVDF-based filter.

[0186] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polytetrafluoroethylene-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PVDF-based filter.

[0187] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polypropylene fleece-based filter, the depth filter comprises 2 to 8 layers of acrylic acid-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a PES-based filter.

[0188] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a pre-filter based on an absorbent glass wool material, the depth filter comprises 2 to 8 layers of acrylic-based filter media, the anion exchange adsorbent medium is an AEX hybrid medium, and the bioburden reduction filter is a PES-based filter.

[0189] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a pre-filter based on mixed cellulose esters, the depth filter comprises 2 to 8 layers of acrylic acid-based filter media, the anion exchange adsorbent media is an AEX mixed media, and the bioburden reduction filter is a PES-based filter.

[0190] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a nylon membrane-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a PES-based filter.

[0191] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a glass and quartz fiber-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a PES-based filter.

[0192] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polyvinyl chloride-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic acid-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a PES-based filter.

[0193] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polytetrafluoroethylene-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic acid-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a PES-based filter.

[0194] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polypropylene fleece-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a PES-based filter.

[0195] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a pre-filter based on an absorbent glass wool material, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent medium is an AEX hybrid medium, and the bioburden reduction filter is a PES-based filter.

[0196] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a pre-filter based on mixed cellulose esters, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is an AEX mixed media, and the bioburden reduction filter is a PES-based filter.

[0197] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a nylon membrane-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based depth filter medium, the anion exchange adsorbent medium is an AEX hybrid medium, and the bioburden reduction filter is a PES-based filter.

[0198] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a glass and quartz fiber-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a PES-based filter.

[0199] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polyvinyl chloride-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a PES-based filter.

[0200] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polytetrafluoroethylene-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a PES-based filter.

[0201] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polypropylene fleece-based pre-filter, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a PES-based filter.

[0202] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a pre-filter based on an absorbent glass wool material, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent medium is an AEX hybrid medium, and the bioburden reduction filter is a PES-based filter.

[0203] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a pre-filter based on mixed cellulose esters, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent media is an AEX mixed media, and the bioburden reduction filter is a PES-based filter.

[0204] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a nylon membrane-based pre-filter, the depth filter comprises 2 to 8 layers of glass-based depth filter medium, the anion exchange adsorbent medium is an AEX hybrid medium, and the bioburden reduction filter is a PES-based filter.

[0205] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a glass and quartz fiber-based pre-filter, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a PES-based filter.

[0206] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polyvinyl chloride-based pre-filter, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a PES-based filter.

[0207] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polytetrafluoroethylene-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PES-based filter.

[0208] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polypropylene fleece-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic acid-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PES-based filter.

[0209] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a pre-filter based on an absorbent glass wool material, the depth filter comprises 2 to 8 layers of acrylic-based filter media, the anion exchange adsorbent medium is a strong AEX medium, and the bioburden reduction filter is a PES-based filter.

[0210] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a pre-filter based on mixed cellulose esters, the depth filter comprises 2 to 8 layers of acrylic acid-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PES-based filter.

[0211] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a nylon membrane-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PES-based filter.

[0212] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a glass and quartz fiber-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PES-based filter.

[0213] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polyvinyl chloride-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic acid-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PES-based filter.

[0214] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polytetrafluoroethylene-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic acid-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PES-based filter.

[0215] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polypropylene fleece-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PES-based filter.

[0216] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a pre-filter based on an absorbent glass wool material, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent medium is a strong AEX medium, and the bioburden reduction filter is a PES-based filter.

[0217] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a pre-filter based on mixed cellulose esters, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PES-based filter.

[0218] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a nylon membrane-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based depth filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PES-based filter.

[0219] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a glass and quartz fiber-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PES-based filter.

[0220] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polyvinyl chloride-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PES-based filter.

[0221] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polytetrafluoroethylene-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PES-based filter.

[0222] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polypropylene fleece-based pre-filter, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PES-based filter.

[0223] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a pre-filter based on an absorbent glass wool material, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion adsorbent medium is a strong AEX medium, and the bioburden reduction filter is a PES-based filter.

[0224] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a pre-filter based on mixed cellulose esters, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PES-based filter.

[0225] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a nylon membrane-based pre-filter, the depth filter comprises 2 to 8 layers of glass-based depth filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PES-based filter.

[0226] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a glass and quartz fiber-based pre-filter, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PES-based filter.

[0227] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polyvinyl chloride-based pre-filter, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PES-based filter.

[0228] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polytetrafluoroethylene-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a PES-based filter.

[0229] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polypropylene fleece-based filter, the depth filter comprises 2 to 8 layers of acrylic acid-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a polyamide-based filter.

[0230] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a pre-filter based on an absorbent glass wool material, the depth filter comprises 2 to 8 layers of acrylic-based filter media, the anion exchange adsorbent medium is an AEX hybrid medium, and the bioburden reduction filter is a polyamide-based filter.

[0231] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a pre-filter based on mixed cellulose esters, the depth filter comprises 2 to 8 layers of acrylic acid-based filter media, the anion exchange adsorbent media is an AEX mixed media, and the bioburden reduction filter is a polyamide-based filter.

[0232] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a nylon membrane-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a polyamide-based filter.

[0233] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a glass and quartz fiber-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a polyamide-based filter.

[0234] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polyvinyl chloride-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic acid-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a polyamide-based filter.

[0235] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polytetrafluoroethylene-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic acid-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a polyamide-based filter.

[0236] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polypropylene fleece-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a polyamide-based filter.

[0237] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a pre-filter based on an absorbent glass wool material, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent medium is an AEX hybrid medium, and the bioburden reduction filter is a polyamide-based filter.

[0238] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a pre-filter based on mixed cellulose esters, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is an AEX mixed media, and the bioburden reduction filter is a polyamide-based filter.

[0239] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a nylon membrane-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based depth filter medium, the anion exchange adsorbent medium is an AEX hybrid medium, and the bioburden reduction filter is a polyamide-based filter.

[0240] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a glass and quartz fiber-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a polyamide-based filter.

[0241] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polyvinyl chloride-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a polyamide-based filter.

[0242] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polytetrafluoroethylene-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a polyamide-based filter.

[0243] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polypropylene fleece-based pre-filter, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a polyamide-based filter.

[0244] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a pre-filter based on an absorbent glass wool material, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent medium is an AEX hybrid medium, and the bioburden reduction filter is a polyamide-based filter.

[0245] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a pre-filter based on mixed cellulose esters, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent media is an AEX mixed media, and the bioburden reduction filter is a polyamide-based filter.

[0246] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a nylon membrane-based pre-filter, the depth filter comprises 2 to 8 layers of glass-based depth filter medium, the anion exchange adsorbent medium is an AEX hybrid medium, and the bioburden reduction filter is a polyamide-based filter.

[0247] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a glass and quartz fiber-based pre-filter, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a polyamide-based filter.

[0248] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polyvinyl chloride-based pre-filter, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent media is an AEX hybrid media, and the bioburden reduction filter is a polyamide-based filter.

[0249] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polytetrafluoroethylene-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a polyamide-based filter.

[0250] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polypropylene fleece-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a polyamide-based filter.

[0251] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a pre-filter based on an absorbent glass wool material, the depth filter comprises 2 to 8 layers of acrylic-based filter media, the anion exchange adsorbent medium is a strong AEX medium, and the bioburden reduction filter is a polyamide-based filter.

[0252] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a pre-filter based on mixed cellulose esters, the depth filter comprises 2 to 8 layers of acrylic acid-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a polyamide-based filter.

[0253] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a nylon membrane-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a polyamide-based filter.

[0254] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a glass and quartz fiber-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a polyamide-based filter.

[0255] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polyvinyl chloride-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic acid-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a polyamide-based filter.

[0256] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polytetrafluoroethylene-based pre-filter, the depth filter comprises 2 to 8 layers of acrylic acid-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a polyamide-based filter.

[0257] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polypropylene fleece-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a polyamide-based filter.

[0258] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a pre-filter based on an absorbent glass wool material, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent medium is a strong AEX medium, and the bioburden reduction filter is a polyamide-based filter.

[0259] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a pre-filter based on mixed cellulose esters, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a polyamide-based filter.

[0260] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a nylon membrane-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based depth filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a polyamide-based filter.

[0261] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a glass and quartz fiber-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a polyamide-based filter.

[0262] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polyvinyl chloride-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a polyamide-based filter.

[0263] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polytetrafluoroethylene-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a polyamide-based filter.

[0264] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polypropylene fleece-based pre-filter, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a polyamide-based filter.

[0265] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a pre-filter based on an absorbent glass wool material, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent medium is a strong AEX medium, and the bioburden reduction filter is a polyamide-based filter.

[0266] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a pre-filter based on mixed cellulose esters, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a polyamide-based filter.

[0267] In some embodiments of the methods and systems disclosed herein, the pre-filter medium is a nylon membrane-based pre-filter, the depth filter comprises 2 to 8 layers of glass-based depth filter medium, the anion exchange adsorbent medium is a strong AEX medium, and the bioburden reduction filter is a polyamide-based filter.

[0268] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a glass and quartz fiber-based pre-filter, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a polyamide-based filter.

[0269] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polyvinyl chloride-based pre-filter, the depth filter comprises 2 to 8 layers of glass-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a polyamide-based filter.

[0270] In some embodiments of the methods and systems disclosed herein, the pre-filter media is a polytetrafluoroethylene-based pre-filter, the depth filter comprises 2 to 8 layers of cellulose-based filter media, the anion exchange adsorbent media is a strong AEX media, and the bioburden reduction filter is a polyamide-based filter.

[0271] Viral capsid preparations

[0272] The methods and systems disclosed herein can be used to separate rAAV capsid particles from host-producing cell-derived impurities (such as nucleic acids, proteins, peptides, lipopolysaccharides, cell membranes, and helper viral particles) from viral capsid preparations (e.g., viral capsid preparations produced by methods designed to generate recombinant viral particles containing heterologous nucleic acids). Typically, the rAAV capsid particles in a given viral capsid preparation are capsid particles of the same virus and the same serotype. In some embodiments, the capsid is derived from the AAV capsid of serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, rh10, or hu37, or a variant thereof. In some embodiments, the capsid is derived from the AAV capsid of serotype 8 or 9, or a variant thereof. In some embodiments, the capsid is derived from the AAV capsid of serotype 8, or a variant thereof. In some embodiments, the capsid is derived from the AAV capsid of serotype 9, or a variant thereof. In some embodiments, the capsid is derived from the AAV capsid of serotype rh10 or hu37, or a variant thereof. In some embodiments, the capsid is derived from the AAV capsid of serotype rh10 or a variant thereof. In some embodiments, the capsid is derived from the AAV capsid of serotype hu37 or a variant thereof.

[0273] Throughout this specification, where a system or method is described as having, including, or comprising specific components or steps, it is anticipated that additional systems or methods of this disclosure are substantially composed of or constituted by the listed components or steps.

[0274] In this application, when an element or component is referred to as being included in and / or selected from the list of enumerated elements or components, it will be understood that the element or component can be any one of the enumerated elements or components, or the element or component can be selected from a group consisting of two or more of the elements or components.

[0275] Furthermore, it will be understood that the elements and / or features described herein can be combined in various ways without departing from the spirit and scope of this disclosure, whether explicit or implicit. In other words, while embodiments have been described and depicted in a manner that allows for clear and concise application writing and drawing, it is intended and will be understood that embodiments can be combined or separated in various ways without departing from the scope of this teaching and one or more disclosures. For example, it will be understood that all features described and depicted herein can be applied to all aspects of one or more disclosures described and depicted herein. All features disclosed in this specification can be combined in any combination. Each feature disclosed in this specification can be replaced by an alternative feature for the same, equivalent, or similar purpose.

[0276] It will be understood that, unless otherwise understood from the context and use, the expression "at least one" individually includes each of the objects listed following the expression, as well as various combinations of two or more of the listed objects. Unless otherwise understood from the context, the expression "and / or" relating to three or more listed objects will be understood to have the same meaning.

[0277] The use of the terms “include, include, including,” “have, has, having,” and “contain, contains, or containing” will be understood, including their grammatical equivalents, which are generally considered open-ended and non-restrictive, e.g., do not exclude additional unlisted elements or steps unless otherwise explicitly stated or understood from the context.

[0278] Any and all instances or exemplary language used herein, such as “for instance,” “such as,” “for example / eg,” or “include,” are intended only to better illustrate this disclosure and, unless otherwise stated, do not constitute a limitation on the scope of this disclosure. The language in this specification should not be construed as indicating that any unclaimed element is necessary for practicing the subject matter of this disclosure.

[0279] It should be understood that this disclosure is not limited to the specific methods, schemes, materials, and reagents described, as they can vary. It should also be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of this disclosure as covered by the appended claims.

[0280] All publications, patents and patent applications (including any figures, sequences and appendices therein) mentioned throughout this specification are incorporated in their entirety by reference for all purposes, to the extent that each individual publication, patent or patent application, figure, sequence or appendice is expressly and individually indicated to be incorporated in its entirety by reference for all purposes.

[0281] Example

[0282] The present invention system and method, which are now generally described, will be more readily understood by referring to the following embodiments. These embodiments are included for the purpose of illustrating certain aspects and embodiments of this disclosure and are not intended to limit this disclosure.

[0283] Clarifying the harvested material from high-cell-density production cell lines used to produce rAAV particles, aided by virus isolation, is a necessary step in the bioprocessing and manufacturing of rAAV-based pharmaceutical products. The following studies disclose the testing and identification of specific filters used to develop the clarification and filtration system disclosed herein to remove contaminants, impurities (including cell aggregates), and helper viruses from the harvested rAAV production cell lysate.

[0284] Example 1: The effect of adding a pre-filter on the pressure differential of the depth filter in the filter string

[0285] Objectives and Research Design: In this study, two different filter cascades were used to process the same feed material to demonstrate the effect of adding a pre-filter for primary filtration. Figure 1A-1B Using an enhanced method that implements the batch feeding and / or perfusion strategy described herein, feed was applied from a bioreactor derived from AAV PCL (in a 250 L scale bioreactor at 1.5 × 10⁻⁶ ppm). 7 Lysates from the same batch (peak cell density growth per ml) yielded the same feed material containing the same levels of rAAV particles, impurities, and Ad5 particles. For the first tandem ( Figure 2A The feed (coarse harvest) is passed through a 23 cm channel. 2 Millistak+ ® HC Pro D0SP (MilliporeSigma; MD0SP23CL3) filter treatment. To evaluate the effect of adding a pre-filter, for the second tandem ( Figure 2B The feed will pass through a 0.018 m 2 50-μm Sartopure ® PP3 (Sartorius; 5051350P4) pre-filter, followed by 23 cm 2 Millistak+ ®HCPro D0SP filter treatment. Filtration is carried out at a constant flow rate, with the flow rate controlled by a peristaltic pump (Watson-Marlow 120). The inlet pressure of each filter is monitored by a disposable pressure transducer (PendoTECH; PRESS-S-000) and a PendoTECH data acquisition system. The operating flux is fixed at 75 L / m for the D0SP filter. 2 h. Before processing the feed material, flush with water through PP3 and DOSP filters. Equilibrate the system using a solution (pH 8.0) containing 20 mM Tris, 350 mM NaCl, and 0.001% (w / v) poloxamer 188. After priming and equilibration, process the crude harvest through a cascade of filters until the feed is consumed or the DOSP differential exceeds approximately 16 psid.

[0286] Results: The results presented in this paper show that, in the absence of a pre-filter, coarse harvested material can pass through the filter tandem at flow rates exceeding 150 L / m. 2 Stop at time, where the maximum differential pressure saturation value is 16 psid ( Figure 2A However, with the addition of a pre-filter, the flow rate of the filter string increased to 200 L / m. 2 The pressure difference is approximately 20 psid ( Figure 2B ).

[0287] Conclusion: Based on the findings presented in this paper, adding a pre-filter with an appropriate pore size improves the throughput (L / m) of the DOSP depth filter. 2 This may be due to the grading effect, where larger particles are retained by the pre-filter, thus reducing the likelihood of fouling on the DOSP depth filter.

[0288] Example 2: Comparison of throughput capacity of conventional depth filters and adsorption filters in reducing bioburden.

[0289] Objectives and Research Design: In this study, three different filter arrays were used to process comparable feed materials to demonstrate the effectiveness of using adsorption filters for secondary filtration. Figure 1B For all three series, filtering is performed at a constant flow rate, where it is carried out by a peristaltic pump (Avantor). ® MasterFlex ® L / S ® (MFLX07522-20) controls the flow rate. For the first tandem (depth filter plus bioload reduction filter) ( Figure 3A The feed (coarse harvested material) is passed through a 0.018 m...2 The 50-μm Sartopure PP3 (Sartorius; 5051350P4) pre-filter treats the outlet into two, which are then passed through two 0.027 m... 2 (Total filtration area is 540 cm²) 2 Milstak+ ® The filtrates from the two DOSP filters were combined using an HC Pro DOSP (Millibo Sigma; MD0SP027H1) filter and then passed through a 0.027 m... 2 Millistak+ ® The sample is treated with an F0HC (Millibos Sigma; MF0HC027H1) filter and finally passed through a 0.014 m³ filter. 2 Millipore Express SHC (Millipore Sigma; KHGES015FB3) 0.5 / 0.2-μm filter treatment. Operating flux is fixed at 75 L / m compared to the DOSP filter. 2 h. For the second ( Figure 3B ) and the third string ( Figure 3C An intermediate pool is generated to serve as the feed. The coarse harvested material (equivalent to the first string) is fed through a 0.018 m... 2 The 50-μm Sartopure PP3 filter processes the water, splitting the outlet into two, and passing through two 0.027 m... 2 (Total filtration area is 540 cm²) 2 Millistak+ ® HC Pro DOSP filter treatment. Process fluid from the filter cascade is collected, and this intermediate serves as feed for the second and third cascades. In the second cascade, the DOSP filtrate intermediate is passed through a 0.0340 m... 2 Harvest RC (3M Purification Inc.; EMP513HRC2FA) is an AEX-based filter (adsorption filter A), followed by 0.014 m 2 Processed using a Millipore Express SHC 0.5 / 0.2-μm filter. In the third tandem, the DOSP filtrate intermediate is passed through a 0.0170 μm filter. 2 Emphaze (3M Purification; EMP513AEX020R) is an AEX-based filter (adsorption filter B), followed by 0.014 m 2Millipore Express SHC 0.5 / 0.2-μm filter treatment. For the primary filtration steps (PP3 and DOSP), the operating flux is fixed at 75 L / m relative to the DOSP filter. 2 h. For the two-stage filtration steps (adsorption filter and SHC), the operating flux is fixed at 50 and 100 L / m, respectively, relative to adsorption filter A (second tandem) and adsorption filter B (third tandem). 2 • h. The inlet pressure of each filter was monitored using a disposable pressure transducer (PendoTECH; PRESS-S-000) and a PendoTECH data acquisition system. Each filter was pre-flushed before processing the feed material. The system was equilibrated using a solution (pH 8.0) containing 20 mM Tris, 350 mM NaCl, and 0.001% (w / v) poloxamer 188. After pre-flushing and equilibration, the feed material was processed through the filter tandem until the feed was consumed or when the inlet pressure exceeded 20 psi.

[0290] Results: The results presented in this paper show that coarse harvested material flows through a first cascade of filters, including a conventional depth filter and a bioburden reduction filter, at flow rates exceeding approximately 300 L / m. 2 The flow rate is stopped at a maximum differential pressure saturation of 20 psid. A second filter cascade with adsorption filter A increases the flow rate to 650 L / m³. 2 This corresponds to a pressure difference of 12 psid. A second filter cascade with adsorption filter A increases the flow rate to 800 L / m³. 2 This corresponds to a pressure difference of 12 psid.

[0291] Conclusion: The results presented in this paper demonstrate that the use of an AEX-based clarification filter in secondary filtration improves the throughput (L / m³) of the bioburden reduction filter (0.5 / 0.2 μm filter). 2 The increased flow rate observed under reduced pressure differentials is likely because scale / pore-clogging material is better retained in these filters compared to conventional depth filters such as F0HC filters.

[0292] Example 3: Comparison of pressure profiles of various commercially available AEX-based adsorbent media.

[0293] Objectives and Study Design: In this study, three different adsorbent separation media were evaluated without being limited by pressure buildup on the filter due to downstream bioload reduction. Filtration experiments were conducted using an ÄKTA™ Avant 25 unit (Stenford). Inlet pressure was monitored via an online pressure sensor, sample loop valve, outlet valve, several universal valves applicable to different flow paths, conductivity sensor, pH sensor, UV detector (0.2 cm path length), and built-in fraction collector. For all three devices testing the three different adsorbent separation media, filtration was performed at a constant flow rate, controlled by an Avant 25 dual-head piston pump. For the second ( Figure 3B ) and the third string ( Figure 3C An intermediate pool is generated to serve as the feed. The coarse harvested material (equivalent to tandem one) is fed through a 0.018 m... 2 The 50-μm Sartopure PP3 (Sartorius; 5051350P4) filter treats the outlet, splitting it into two and passing it through two 0.027 μm filters. 2 (Total filtration area is 540cm²) 2 Millistak+ ® HC Pro DOSP (Millibosigma; MD0SP027H1) filter treatment. The treated fluid from the filter tandem is collected, and this intermediate serves as the feed for comparison among three adsorbent separation media. Three different AEX-based devices were compared: 1) 0.2-mL Natrix ® 1) 1) Millibor Sigma; NXF-00 (adsorbent hydrogel); 2) 1.4 mL Harvest RC (3M Purification; BC4, EMP201HRC2FA) (adsorbent filter A); and 3) 1.4 mL Emphaze (3M Purification; BV1, EMP201AEX020R) (adsorbent filter B). Each filter was pre-washed according to the supplier's recommendations before processing the feed material. The system was equilibrated using a solution (pH 8.0) containing 20 mM Tris, 350 mM NaCl, and 0.001% (w / v) poloxamer 188. After pre-washing and equilibration, the feed material was processed through the AEX-based device until the feed was consumed or when the differential pressure exceeded 30 psid. The flow rate was maintained at 0.5 media volumes / min.

[0294] Results: The study described in this paper shows that adsorbed hydrogen exhibits rapid clogging, indicated by a maximum pressure differential greater than 15 psid achieved as the loading volume increases from 25 to 125 throughput units. In contrast, two AEX-based adsorbed filters, namely adsorbed filter A and adsorbed filter B, respectively depicted a maximum pressure differential of less than approximately 2 psid achieved when the loading volume capacity is increased to approximately 150 throughput units. Figure 4 Therefore, it shows a reduction in congestion.

[0295] Conclusion: Multiple factors determine the adsorption capacity and throughput of adsorption filters. The adsorption filter equipment used in the clarification study was specifically designed for clarification. In contrast, other AEX media on the market with comparable or higher AEX capacities are designed for chromatographic applications. Natrix ® The Q is considered to have the highest AEX capacity among commercially available AEX-based adsorbers. This is presumably due to Natrix's smaller pore size and device design. ® Q (adsorbent hydrogel) exhibits immediate pore clogging. Adsorbent filter Harvest ® RC and Emphaze ® There are also design differences. Compared to the latter, the former has a lower AEX capacity and a denser built-in bioburden reduction filter. The results disclosed in this paper show that, before pressure buildup, the Emphaze (adsorbent filter B) exhibits a greater throughput than the Harvest RC (adsorbent filter A). One of these two factors—the AEX capacity or pore size distribution of the built-in bioburden reduction filter—may primarily contribute to the difference in throughput.

[0296] Example 4: Harvest clarifier pressure profile for multi-stage filter arrays used in 50-L scale production

[0297] Objectives and Study Design: The study described herein is a 50-L scale-up demonstration to evaluate the complete filtration assembly using an exemplary process-scale apparatus of the cell lysate clarification and filtration system disclosed herein. The feed (coarse harvest) was passed through a 0.12m... 2 50-μm Sartopure ® Pre-filter treatment with PP3 (Sartorius; 5055350P8) at 345 L / m 2 The flux challenge is to achieve 351 L / m³. 2 After pre-filtration, the process feed is fed into two 0.33 m... 2 (Total filtration area is 66 m²) 2 Millistak+ ®In the HC Pro DOSP (Millibo Sigma; MD0SP03FS1) depth filter, at 63 L / m 2 The flux challenge is to achieve 64 L / m³. 2 After depth filtering, it passes through two 0.23 m... 2 (Total filtration area is 46 m²) 2 Emphaze ® (3M Purification Company; EMP710AEX020R) Based on AEX adsorption filter treatment, at 90 L / m 2 The flux challenge is to achieve 92 L / m³. 2 The filter string is set at 0.13 m. 2 The Opticap™ XLT3 (Millibo Sigma; KHGES03HH3) 0.5 / 0.2-μm bioburden reduction filter was used to achieve a flow rate of 318 L / m³. 2 The flux challenge is to achieve 324 L / m³. 2 Each filter was pre-washed before processing the feed material. The system was equilibrated using a solution (pH 8.0) containing 20 mM Tris, 350 mM NaCl, and 0.001% (w / v) poloxamer 188. After pre-washing and equilibration, the feed material was processed.

[0298] Results: The study described in this paper shows that the pressure differential at each filtration step remains below approximately 10 psid, with a corresponding increase in throughput volume (L / m³). 2 This pressure differential is below the recommended 20 psid benchtop unit pressure differential limit. The results described herein help determine the operating parameters defined by the optimal flux limits, volumetric challenges, and pressure differential limits for the different filter components of the clarification and filtration systems disclosed herein.

[0299] Table 1: Operating parameters of the disclosed clarification and filtration systems

[0300]

[0301] Conclusion: This scale-up evaluation at the 50-L scale shows that the performance (throughput) of the process-scale equipment is comparable to that of the bench-scale equipment.

[0302] Example 5: Comparison of turbidity of crude harvest and clarified filtrate from two pilot-scale batches using an adsorption filter for secondary filtration.

[0303] Objectives and Study Design: The study described herein was conducted to evaluate the turbidity of aliquots of crude (pre-filtered) and clarified harvest (post-filtered) from two different production batches having comparable feed materials, under the filtration conditions described below, using the clarification and filtration system disclosed herein. The change in turbidity of the filtrate relative to the feed material was used as an indicator of the effectiveness of the disclosed clarification and filtration system in removing impurities from the feed material.

[0304] Production batch 1 is a scaled-up demonstration evaluating the entire filter assembly using representative process-scale equipment. The feed (coarse harvest) is passed through a 0.65 m... 2 Treatment with a 50-μm Sartopure® PP3 (Sartorius; 5057350P1) filter at 248 L / m 2 The flux challenge is to reach 389 L / m³. 2 Then the process feed is fed into three 0.77 m... 2 (Total filtration area is 2.3 m²) 2 Millistak+ ® In the HC Pro D0SP (Millibo Sigma; MD0SP07FS1) filter, at 70 L / m 2 The flux challenge is to achieve 109 L / m³. 2 After that, through two 1.61 m 2 (Total filtration area is 3.22 m²) 2 Treatment with a Harvest™ RC (3M Purification Company; EMP770HRC2FA) filter at 50 L / m 2 The flux challenge is to achieve 78 L / m³. 2 The filter string is divided into two 0.49 m... 2 (Total filtration area is 0.98 m²) 2 Opticap® XLT10 (Millibo Sigma; KHGES03HH3) 0.5 / 0.2-μm filter finish, at 329 L / m 2 The flux challenge is to achieve 258 L / m³. 2 Production batch 2 comprises aliquots of samples taken from the same filtration experiments and conditions as described in Example 4.

[0305] Results: The study described in this paper shows that the clarification and filtration cascades used in both production batches 1 and 2 significantly reduced the turbidity of the resulting final filtrate compared to the corresponding feed materials fed into the system. Figure 6 ).

[0306] Conclusion: Based on the results described herein, the turbidity of the clarified harvest pool indicates that the filtrate generated by filtering the feed material through the clarification and filtration system disclosed herein has sufficient purity to continue processing with minimal risk of impacting subsequent unit operations used for purifying pharmaceutical products.

[0307] Example 6: Evaluation of the Loaded Conductivity of anion adsorption filters

[0308] Objectives and Study Design: This study determined the effect of the loading conductivity of an anion exchange filter (Q filter) on rAAV recovery and impurity level reduction (determined by turbidity) from the influent applied to the Q filter. To demonstrate rAAV binding to the membrane, a linear conductivity gradient period followed the sample application / flow-through period. Specifically, the effects of low, medium, and high conductivity of the loading material on rAAV recovery and turbidity of the purified filtrate were determined.

[0309] Results: The elution profile of the rAAV capsid (elution profile at UV254 and UV280) was determined as a function of linearly increasing loading material conductivity and loading volume. No significant change was observed in the UV absorbance traces at 280 or 254 nm wavelengths, indicating that rAAV was stripped from the Q filter. Figure 7 Table 2 below depicts the percentage of rAAV recovery and turbidity of the influent filtrate applied to the Q filter. As shown in Table 2, at low conductivity loading, several impurity groups bind to the Q filter along with the product rAAV particles, resulting in a low percentage of product rAAV recovery and low filtrate turbidity. At high conductivity loading, the impurity groups and rAAV do not adhere to the adsorbent filter, resulting in a high percentage of product rAAV recovery, but with a high turbidity filtrate. Adjusting to a medium conductivity loading balances high rAAV recovery and high impurity removal, as depicted by the low turbidity of the filtrate.

[0310] Table 2: Load Conductivity Optimization

[0311]

[0312] Conclusion: The results presented in this paper demonstrate that the recovery of rAAV and the reduction of impurities from the influent applied to the anion adsorber filtrate are optimal at moderate conductivity of the loaded material.

[0313] Example 7: Simulation of adenovirus 5 (Ad5) loading density on an anion exchange filter

[0314] Objectives and Study Design: This study describes a loading density simulation to account for typical process variability in feed material filtration. Assuming a fixed filter bed volume of 78.4 L and a conservative dynamic binding capacity (DBC), process variability was assessed in terms of expected volumetric loading, Ad5 loading expressed as genome copies / loading volume (Ad5, GC / L-MV), and penetration of AEX Emphaze capsules. Probability distributions of expected upstream treatment outputs (bioreactor working volume and Ad5 titer) are based on historical therapeutic transgenic, pilot-scale, and small-scale Ambr250 bioreactor studies carrying rAAV. The input, fixed, and output variables used are provided in Tables 3, 4, and 5, respectively. The simulation was run 1000 times to generate the output data. Histograms of loading density events are shown below. Figure 8 In the middle, simulate 1000 iterations to generate output data.

[0315] Table 3. Loading Density Simulation - Input Variables

[0316]

[0317] Table 4. Loading density simulation - fixed variables

[0318]

[0319] Table 5. Loading Density Simulation - Output Variables

[0320]

[0321] Results: The results of the loading density simulations described in this paper are summarized in... Figure 8 Based on the results described in this paper, at 3 × 10⁻⁶ 6 Up to 5 × 10 6 Under the GC / load volume (L-MV) Ad5 loading challenge, 91.8% of Ad5 was retained by the anion adsorption filter, indicating that the Ad5 concentration in the feed material is lower than that of DBC.

[0322] Conclusion: Based on the results described herein, the loading schemes for the dynamic binding capacity of the anion exchange filter used in the methods and systems disclosed herein are described as follows: (a) the incoming Ad5 concentration in the filtrate entering the anion exchange filter is less than 0.1% of the filter's DBC; (b) the incoming Ad5 concentration in the filtrate entering the anion exchange filter is greater than 0.1% and less than 1% of the filter's DBC. The expected Ad5 concentration is estimated to be approximately 2 × 10⁻⁶. 10GC / mL, which is typical within the range of the rAAV-based HeLa cell production platform described herein; and (c) the incoming Ad5 concentration in the filtrate entering the anion exchange filter is greater than 1% of the filter's DBC. The Mustang Q step filter can be expected to remove this level of Ad5 concentration, but there may be a threshold Ad5 concentration that increases bioburden and reduces the rate of fouling on the filter.

Claims

1. A method for clarifying cell lysates produced from cell cultures expressing recombinant adeno-associated virus (rAAV) particles, the method comprising: (a) Pass the cell lysate through a pre-filter medium to generate a first filtrate; (b) Passing the first filtrate through a depth filter medium to generate a second filtrate; (c) Passing the second filtrate through an anion adsorber medium to generate a third filtrate; and (d) Pass the third filtrate through a bioload reduction filter to produce clear cell lysate.

2. The method as described in claim 1, wherein, The cell lysate consisted of cells with a density of approximately 1 × 10⁻⁶. 6 To approximately 2 × 10 7 The cell culture expressing rAAV was produced at a rate of 1 cell / mL.

3. The method as described in claim 2, wherein, The cell lysate consisted of cells with a density of approximately 10. 6 The cell culture expressing rAAV was produced at a rate of 1 cell / mL.

4. The method as described in claim 1 or 2, wherein, The cell lysate consisted of cells with a density of approximately 8 × 10⁻⁶. 6 To approximately 2 × 10 7 The cell culture expressing rAAV was produced at a rate of 1 cell / mL.

5. The method according to any one of claims 1 to 4, wherein, The cell lysate has a pH of approximately 7.5 to approximately 8.

0.

6. The method of claim 5, wherein, The cell lysate has a pH of approximately 7.7 to approximately 7.

9.

7. The method according to any one of claims 1 to 6, wherein, The cell lysate contains rAAV particles and one or more of the following: cell complexes, cell aggregates, colloidal aggregates, nucleases, nucleic acids, host cell proteins, lysed cell fragments, and nucleotide fragments.

8. The method according to any one of claims 1 to 7, wherein, The clarified cell lysate retains at least 80% of the total rAAV particles present in the cell lysate.

9. The method of claim 7 or 8, wherein, The cell lysate contained helper virus particles.

10. The method of claim 9, wherein, These helper viral particles are adenovirus particles.

11. The method of claim 10, wherein, These adenovirus particles are adenovirus type 5 (Ad5) particles or their variants or mutant forms.

12. The method of claim 11, wherein, The cell lysate contained approximately 1 × 10⁻⁶ cells. 12 To approximately 3 × 10 12 These Ad5 particles are in GC / ml.

13. The method according to any one of claims 1 to 12, wherein, The volume of the cell lysate is at least 50 L.

14. The method according to any one of claims 1 to 13, wherein, The volume of the cell lysate is at least 250 L.

15. The method according to any one of claims 1 to 14, wherein, The pre-filter media includes any one of the following: polypropylene fleece-based pre-filters, absorbent glass fleece-based pre-filters, mixed cellulose esters, nylon membrane pre-filters, glass and quartz fiber pre-filters, polyvinyl chloride-based filters, and polytetrafluoroethylene-based filters.

16. The method according to any one of claims 1 to 15, wherein, The pre-filter medium has a pore size of approximately 20 μm to approximately 75 μm.

17. The method of claim 16, wherein, The pre-filter medium has a pore size of approximately 50 μm.

18. The method according to any one of claims 1 to 17, wherein, Passing the cell lysate through the pre-filter medium increases the volumetric capacity of the depth filter by at least 25%.

19. The method according to any one of claims 1 to 18, wherein, Passing the cell lysate through the pre-filter medium increases the filtration capacity of the depth filter by approximately 30 to approximately 50 L / m³. 2 .

20. The method according to any one of claims 1 to 19, wherein, The flow rate of the cell lysate in the pre-filter medium is approximately 225 to approximately 925 L / m. 2 h.

21. The method according to any one of claims 1 to 17, wherein, The pre-filter medium has a concentration of approximately 300 to approximately 700 L / m³. 2 Volume capacity.

22. The method according to any one of claims 1 to 21, wherein, The pressure differential in the pre-filter medium is approximately 1 to approximately 5 psi.

23. The method according to any one of claims 1 to 22, wherein, The depth filter media includes any one of cellulose-based filter media, glass-based filter media, and acrylic-based filter media.

24. The method of claim 23, wherein, The depth filter media consists of 2 to 8 layers of the filter media.

25. The method of claim 24, wherein, The depth filter further comprises either diatomaceous earth (DE) filter aid or silica filter aid.

26. The method according to any one of claims 23 to 25, wherein, The depth filter media includes at least one polypropylene fiber pulp, a nonwoven fiber layer, or a combination thereof.

27. The method according to any one of claims 23 to 26, wherein, The depth filter media further contains a cationic binder.

28. The method according to any one of claims 23 to 27, wherein, The flow rate of the first filtrate in the depth filter medium is approximately 50 to approximately 150 L / m. 2 h.

29. The method according to any one of claims 23 to 28, wherein, The volumetric capacity of the depth filter media is approximately 70 to approximately 200 L / m³. 2 .

30. The method according to any one of claims 23 to 29, wherein, The pressure differential in the depth filter medium is approximately 1 to approximately 18 psi.

31. The method according to any one of claims 23 to 30, wherein, The depth filter media consists of a first layer of cellulose fibers and a second layer of cellulose, diatomaceous earth (DE) filter aid, and cationic binder.

32. The method according to any one of claims 23 to 30, wherein, The depth filter media comprises a first layer of nonwoven fibers, a second layer of polypropylene fiber pulp, and a third and fourth layer, the third and fourth layers containing polyacrylic acid fiber pulp, silica filter aid, and cationic binder.

33. The method according to any one of claims 23 to 30, wherein, The depth filter media comprises six layers of polypropylene fiber and nonwoven fiber, a second layer of cellulose fiber, and a third layer of cellulose, diatomaceous earth (DE) filter aid, and cationic binder.

34. The method according to any one of claims 1 to 33, wherein, The anion adsorber medium is either a strong anion exchange chromatography (AEX) medium or a mixed AEX medium.

35. The method of claim 34, wherein, The strong AEX medium is Sartobind. ® Q medium, Mustang ® Q medium or Natrix ® Any of the following media: Q.

36. The method of claim 34, wherein, The AEX mixed medium includes AEX chromatographic medium and polyamide membrane.

37. The method of claim 34, wherein, The AEX mixed media consists of AEX chromatographic media and a polyethersulfone (PES) membrane.

38. The method of any one of claims 36 to 37, wherein, The AEX chromatographic medium is a quaternary ammonium salt functional AEX medium.

39. The method of claim 38, wherein, This quaternary ammonium salt functional AEX medium is a nonwoven medium.

40. The method of claim 38, wherein, The AEX chromatographic medium was 3M Polisher. ® ST media, Harvest ® RC media or Emphaze ® Any type of AEX medium.

41. The method according to any one of claims 36 to 40, wherein, The pore size of the polyamide membrane or the PES membrane is about 0.1 to about 0.5 mm.

42. The method of claim 41, wherein, The pore size of the polyamide membrane or the PES membrane is 0.2 mm.

43. The method according to any one of claims 34 to 42, wherein, The flow rate of the second filtrate in the anion adsorber medium is approximately 50 to approximately 200 L / m. 2 h.

44. The method according to any one of claims 34 to 43, wherein, The volumetric capacity of the anion adsorber medium is approximately 70 to approximately 200 L / m³. 2 .

45. The method according to any one of claims 34 to 44, wherein, The pressure differential of the anion adsorber medium is approximately 1 to approximately 10 psi.

46. ​​The method of any one of claims 34 to 45, wherein, The conductivity of the filter load of the anion adsorber medium is approximately 16 to approximately 40 mS / cm.

47. The method of claim 46, wherein, The conductivity of the filter load is approximately 18 to approximately 37 mS / cm.

48. The method according to any one of claims 1 to 47, wherein, The bioburden reduction filter includes any one of the following: a polyvinylidene fluoride (PVDF) based filter, a PES based filter, and a polyamide based filter.

49. The method according to any one of claims 1 to 48, wherein, The third filtrate reduces the filter flow rate by approximately 300 to approximately 700 L / m³ through this bioburden. 2 h.

50. The method according to any one of claims 1 to 49, wherein, The volumetric capacity of this bioburden-reducing filter is approximately 200 to approximately 750 L / m³. 2 .

51. The method according to any one of claims 1 to 50, wherein, The bioburden reduction filter has a differential pressure limit of approximately 20 to approximately 25 psi.

52. A system for clarifying cell lysates produced from cell cultures expressing recombinant adeno-associated virus (rAAV) particles, the system comprising: (a) A first module comprising a pre-filter medium that filters the cell lysate to remove particulate matter ≥ 50 μm in size from the cell lysate to generate a first filtrate; (b) A second module comprising a depth filter medium that filters the first filtrate to remove particulate matter with a size ≥ 1 μm to < 50 μm from the first filtrate to generate a second filtrate; (c) A third module comprising an anion exchanger medium that filters the second filtrate to remove auxiliary virus particles from the second filtrate to generate a third filtrate; as well as (d) A fourth module, comprising a bioburden reduction filter that filters the third filtrate to remove microbial contaminants from the third filtrate to produce a clear cell lysate.

53. The system of claim 52, wherein, The cell lysate consisted of cells with a density of approximately 1 × 10⁻⁶. 6 To approximately 2 × 10 7 The cell culture expressing rAAV was produced at a rate of 1 cell / mL.

54. The system of claim 53, wherein, The cell lysate consisted of cells with a density of approximately 10. 6 The cell culture expressing rAAV was produced at a rate of 1 cell / mL.

55. The system of claim 53, wherein, The cell lysate consisted of cells with a density of approximately 8 × 10⁻⁶. 6 To approximately 2 × 10 7 The cell culture expressing rAAV was produced at a rate of 1 cell / mL.

56. The system as claimed in any one of claims 52 to 55, wherein, The cell lysate has a pH of approximately 7.5 to approximately 8.

0.

57. The system of claim 56, wherein, The cell lysate has a pH of approximately 7.7 to approximately 7.

9.

58. The system as claimed in any one of claims 52 to 57, wherein, These helper viral particles are adenovirus particles.

59. The system of claim 58, wherein, These adenovirus particles are Ad5 particles or their variants or mutant forms.

60. The system of claim 59, wherein, The cell lysate contained approximately 1 × 10⁻⁶ cells. 12 To approximately 3 × 10 12 These Ad5 particles are in GC / ml.

61. The system as claimed in any one of claims 52 to 60, wherein, The volume of the cell lysate is at least 50 L.

62. The system as claimed in any one of claims 52 to 60, wherein, The volume of the cell lysate is at least 250 L.

63. The system as claimed in any one of claims 52 to 62, wherein, The pre-filter medium is any one of the following: polypropylene fleece-based pre-filter, absorbent glass fleece-based pre-filter, mixed cellulose ester, nylon membrane pre-filter, glass and quartz fiber pre-filter, polyvinyl chloride, and polytetrafluoroethylene.

64. The system of claim 63, wherein, The pre-filter medium has a pore size of approximately 20 μm to approximately 75 μm.

65. The system of claim 64, wherein, The pre-filter medium has a pore size of approximately 50 μm.

66. The system of claim 63, wherein, The depth filter media is any one of cellulose-based, glass-based, and acrylic-based filter media.

67. The system of claim 66, wherein, The depth filter media consists of 2-8 layers of this filter media.

68. The system of claim 67, wherein, The depth filter further comprises either diatomaceous earth (DE) filter aid or silica filter aid.

69. The system as claimed in any one of claims 63 to 68, wherein, The depth filter media includes at least one polypropylene fiber pulp, a nonwoven fiber layer, or a combination thereof.

70. The system as claimed in any one of claims 63 to 69, wherein, The depth filter media further contains a cationic binder.

71. The system as claimed in any one of claims 63 to 70, wherein, The depth filter media consists of a first layer of cellulose fibers and a second layer of cellulose, diatomaceous earth (DE) filter aid, and cationic binder.

72. The system as claimed in any one of claims 63 to 70, wherein, The depth filter media comprises a first layer of nonwoven fiber, a second layer of polypropylene fiber pulp, and third and fourth layers of polyacrylic acid fiber pulp, silica filter aid, and cationic binder.

73. The system as claimed in any one of claims 63 to 70, wherein, The depth filter media comprises six layers of polypropylene fiber and nonwoven fiber, a second layer of cellulose fiber, and a third layer of cellulose, diatomaceous earth (DE) filter aid, and cationic binder.

74. The system of claim 52, wherein, The anion adsorber medium is either a strong AEX medium or a mixed AEX medium.

75. The system of claim 74, wherein, The strong AEX medium is any one of Sartobind Q medium, Mustang Q medium, or Natrix Q medium.

76. The method of claim 75, wherein, The AEX mixed medium includes AEX chromatographic medium and polyamide membrane.

77. The method of claim 75, wherein, The AEX mixed media consists of AEX chromatographic media and a polyethersulfone (PES) membrane.

78. The method according to any one of claims 74 to 77, wherein, The AEX chromatographic medium is a quaternary ammonium salt functional AEX medium.

79. The method of claim 78, wherein, This quaternary ammonium salt functional AEX medium is a nonwoven medium.

80. The method of claim 79, wherein, The AEX chromatographic medium was 3M Polisher. ® ST media, Harvest ® RC media or Emphaze ® Any type of AEX medium.

81. The method according to any one of claims 76 to 80, wherein, The pore size of the polyamide membrane or the PES membrane is between about 0.1 and about 0.5 μm.

82. The method of claim 81, wherein, The pore size of the polyamide membrane or the PES membrane is 0.2 μm.

83. The method of claim 82, wherein, The bioburden reduction filter can be any of the following: a PVDF-based filter, a PES-based filter, or a polyamide-based filter.

Citation Information

Patent Citations

  • Engineered producer cell lines and methods of making and using the same

    US20200325455A1

  • Seed culture process for AAV production

    WO2020154607A1

  • Method for the production of aav

    WO2022112218A1

  • Modified batch AAV production systems and methods

    WO2023172491A1